

CURRICULUM VITAE

Meindert Danhof, PharmD, PhD

PERSONAL INFORMATION

Last name : Danhof
First name : Meindert
Date of birth : 30 December 1951
Place of birth : Groningen, The Netherlands
Gender : Male
Office address-1 : Louise de Colignylaan 36, 2341CK Oegstgeest, the Netherlands
Office telephone : + 31 71 517 6105
Office address-2 : Einsteinweg 55, P.O. Box 9502, 2300 RA, The Netherlands
Office telephone : (31) 71 – 527 6351
Office fax : (31) 71 – 527 4277
Mobile telephone : 06 – 539 47 629
E-mail : m.danhof@lacdr.leidenuniv.nl
Citizenship : Dutch

EMPLOYMENT HISTORY

Present positions

2017 – present Emeritus Professor of Pharmacology (*active*), Leiden University, Leiden, the Netherlands
2017 – present Emeritus Professor of Pharmacology (*active*), Leiden University Medical Center, Leiden, the Netherlands

Past positions

2017 – 2021 Pharmacology Consultant, MDPharmacologyAdvice, Oegstgeest, the Netherlands
1996 – 2017 Professor of Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden University, the Netherlands
2007 – 2017 Professor of Pharmacology, Leiden University Medical Center (LUMC)
2005 – 2017 Senior Scientific Advisor, LAP&P Consultants BV, Leiden, the Netherlands
2005 – 2013 Director of Research, Leiden-Amsterdam Center for Drug Research (LACDR), Leiden University, the Netherlands.
1998 – 2005 Chief Scientific Officer, LAP&P Consultants BV, Leiden, the Netherlands
1996 – 2014 Chair Department of Pharmacology, Leiden-Amsterdam Center for Drug Research, Leiden University, Leiden, the Netherlands

1986 – 1996	Associate Professor, Center for Bio-Pharmaceutical Sciences, Leiden University, the Netherlands
1983 – 1986	Assistant Professor, School of Pharmacy, Leiden University, the Netherlands
1984 – 1987	Visiting Scientist, Stanford University Medical School, Stanford, USA.
1980 – 1983	Research Associate, State University of New York, Buffalo, U.S.A.
1976 – 1980	Research Assistant, Leiden University, the Netherlands
1973 – 1976	Teaching Assistant, University of Groningen, the Netherlands

EDUCATION

1998	Board certification as Clinical Pharmacologist in the Netherlands (Honorary Full Member)
1985	Board certification as Experimental Pharmacologist in The Netherlands (Licence number: 85-001)
1984 – 1987	Visiting Scientist with Dr. D.R. Stanski, Stanford University, Stanford, U.S.A.
1980 – 1983	Post Doctoral Research Fellowship under the direction of Dr. G. Levy, State University of New York, Buffalo, U.S.A.
1976 - 1980	Ph.D. in Pharmacology, Promotor: Prof. Dr. D.D. Breimer, Title thesis: “Antipyrine Metabolite Profile as a Tool in the Assessment of the Activity of Different Drug Oxidizing Enzymes in Man”, University of Leiden, The Netherlands (<i>cum Laude</i>)
1976	Pharm.D., University of Groningen, the Netherlands
1975	M.Sc. in Pharmacy with specialization in Pharmacology, Title thesis: “Influence of bile salts on hepatic transport of dibromosulphophtalein”. University of Groningen, the Netherlands (<i>cum Laude</i>)

AWARDS

2019	<i>Host-Madsen Medal</i> , International Pharmaceutical Federation FIP, Abu Dhabi, United Arab Emirates
2018	<i>EUFEPS Presidential Distinction Award</i> , European Federation of Pharmaceutical Sciences (EUFEPS), Athens, Greece
2017	<i>FIP Presidential Citation Award</i> , International Pharmaceutical Federation (FIP), Stockholm, Sweden
2014	<i>Knight of the Order of the Netherlands Lion</i>

2010	<i>Research Achievement Award in Pharmacokinetics, Pharmacodynamics and Drug Metabolism</i> , American Association of Pharmaceutical Scientists (AAPS), New Orleans, USA.
2009	<i>Distinguished Investigator Award</i> , American College of Clinical Pharmacology (ACCP), San Antonio, USA.
2008	<i>Gerhard Levy Distinguished Lectureship in Pharmaceutical Sciences</i> , University at Buffalo, Buffalo, USA.
2006	<i>New Safe Medicines Faster Award</i> , European Federation of Pharmaceutical Sciences (EUFEPS), Copenhagen, Denmark
2004	<i>Rawls-Palmer Award</i> , American Society for Clinical Pharmacology and Therapeutics (ASCPT), Miami, USA.
1998	<i>Fellow</i> , American Association of Pharmaceutical Scientists (AAPS), Boston, USA.
1997	<i>FIP Pharmaceutical Scientist of the Year Award</i> , International Pharmaceutical Federation (FIP), Vancouver, Canada.
1993	<i>Organon Pharmacology Research Prize</i> , Dutch Pharmacological Society (NVF), Noordwijkerhout, the Netherlands
1982	<i>C.J. Kok-Award</i> , C.J. Kok Foundation, Leiden, the Netherlands.
1976	<i>KNMP-Award</i> , Royal Dutch Pharmaceutical Association (KNMP), the Hague, the Netherlands

RESEARCH GRANTS

1. Kinetics for Drug Discovery (K4DD), Innovative Medicines Initiative (IMI; EU). 1 PhD student, 1 Postdoc
2. Mechanism-based PKPD modeling platform 2.0. Top Institute Pharma. 2 PhD students; 5 Post-docs; 2 technical staff; consumables
3. Mechanism-based PKPD modeling platform 1.0 Top Institute Pharma. 10 PhD students; 6 Post-docs; 4 Technical Staff; consumables.
4. Mechanism-based PK-PD modeling of S₁P receptor mediated blood pressure elevation Novartis, Basel; PhD student.
5. Model based characterization of Drug Safety Glaxo Smith Kline, UK; PhD student, consumables.
6. Bridging Strategy for pediatric indicators and ethnic groups; Glaxo Smith Kline, UK: PhD student, consumables.
7. PK-PD analysis of intranasal administration of prosexual agents Pfizer Ltd, UK: PhD students, consumables
8. Development of dopaminergic pro-drugs for programmed iontophoretic delivery into patients with Parkinson's disease Netherlands Foundation for Thechnological Researct STW: PhD student, technician, consumables
9. Mechanism-based PK/PD modelling of subtype selective GABA-receptors in pharmaco-resistant epilepsy Takeda Ltd, Japan: Post-doctoral fellow

10. Integration of disease progression, compliance and placebo effect in the characterisation of the therapeutic response to anti-depressant therapy
Glaxo Smith Kline, UK: PhD student, consumables.
11. Mechanism-based PK/PD modelling of the synergistic interaction of $\alpha_2\delta$ ligands and phosphodiesterase inhibitors in animal models of neuropathic pain.
Pfizer Ltd., UK: Post-doctoral fellow, consumables.
12. Disease progression and therapeutic response in COPD
Glaxo Smith Kline, UK, Post-doctoral fellow, consumables
13. Mechanism-based pharmacokinetic-pharmacodynamic modelling of (synthetic) opiates: Buprenorphine *versus* fentanyl
Grünenthal GmbH, Germany: PhD student, consumables
14. Evaluating the “Free Drug Hypothesis”: mechanism-based pharmacokinetic/ pharmacodynamic modelling
Pfizer Ltd. UK: PhD student, consumables
15. Neurodegeneration, blood-brain barrier transport and drug effects in a new animal model of Parkinsons disease
Eli Lilly and Co, Belgium: PhD student, consumables
16. Integration of disease progression, compliance and placebo effect in the characterisation of the therapeutic response to anti-migraine therapy
Glaxo Smith Kline, UK: PhD student, consumables
17. Pharmacokinetic-pharmacodynamic modelling of Cox-2 inhibitors in animal models of inflammatory pain
Glaxo Smith Kline, UK: PhD student, consumables
18. Mechanism-based pharmacokinetic-pharmacodynamic modelling of neurotransmitter re-uptake inhibitors
Johnson and Johnson, Belgium: PhD student, consumables
19. Mechanisms related to pharmacoresistance in epilepsy: A PET study in experimental animal models on changes in GABA_A mediated inhibition
Netherlands Epilepsy Foundation: PhD student, consumables
20. Pharmacokinetic-Pharmacodynamic modelling of the anti-nociceptive response of (synthetic) opiates
Glaxo Smith Kline, UK: PhD student, consumables
21. Targeting of CRH-receptor antisense probes to and in the central nervous system: application in neuropsychiatry.
Netherlands Research Organisation NWO: PhD student, technician, consumables
22. Pharmacodynamic analysis of anti-epileptic drug-drug interactions *in vivo*.
Netherlands Epilepsy Foundation: PhD student, consumables
23. Adenosine A₁ receptor agonists. Blood-brain barrier transport and PK/PD correlations in neuropathic Pain
Glaxo Smith Kline, UK: PhD student, technician, consumables
24. Transdermal Iontophoretic Delivery of R-apomorphine for the treatment of patients with Parkinson’s disease
Princess Beatrix Foundation: PhD student, MD, technician, consumables
25. Selectivity of adenosine receptor agonists *in vivo*. Assessment of pharmacokinetic-pharmacodynamic correlations
Glaxo Smith Kline, UK: PhD student, consumables
26. Modelling of the pharmacodynamics and tolerance development of anticonvulsants
Netherlands Research Organisation NWO: PhD student, consumables

27. Pharmacokinetic/pharmacodynamic correlations of antidepressants in animal models of anxiety
Institut des Recherches Internationales Servier, France: Post-doctoral fellow, technician, consumables
28. The relation between penetration and effect of cytostatic agents in solid tumours using microdialysis and serial CSF sampling
Netherlands Cancer Research Foundation KWF: PhD student, technician, consumables
29. Development of models to characterise functional tolerance development to anti-epileptic drugs.
Netherlands Organisation for Research on Epilepsy CLEO: technician, consumables
30. Quantitative pharmacokinetic EEG and the relationship between pharmacokinetics and pharmacodynamics of drugs acting on the central nervous system
Netherlands Research Organisation NWO: PhD student, technician, consumables
31. Ageing and the relationship between pharmacokinetics and pharmacodynamics of drugs acting on the central nervous system
Netherlands Research Organisation NWO: PhD student, consumables

PhD SUPERVISION

Ph. D. Students

- | | |
|-------------------|--|
| W. de Witte | The impact of drug-target binding kinetics on <i>in vivo</i> drug effects. <u>19 December 2017</u> (supported by a grant from IMI in the K4DD consortium) |
| S. van Dijkman | Personalized pharmacotherapy in pediatric epilepsy: the path to rational drug and dose selection <u>29 November 2017</u> (Supported by European Union grant agreement no. 261060) |
| E.M.T. van Maanen | Systems pharmacology of the amyloid cascade - unfolding oligomer modulation in Alzheimer's disease (in collaboration with LAP&P Consultants BV) |
| Y. Yamamoto | Development of a generic physiologically based pharmacokinetic model to predict drug target site concentrations in human brain (supported by a grant from TIPharma) |
| V.S.F. Dubois | Reverse engineering of QT(c) interval prolongation – towards a systems pharmacology approach <u>2 May 2017</u> (supported by a grant from TIPharma) |
| A. Strougo | Optimisation of first clinical studies in special populations: towards semi-physiological pharmacokinetics models <u>17 December 2015</u> (supported by a grant from TIPharma) |
| F. Bellanti | From data to models: reducing uncertainty in benefit-risk assessment. Application to chronic iron overload in children <u>24 September 2015</u> |
| J.P. Mochel | Dynamics of the renin-angiotensin aldosterone system in dogs: circadian variations in physiological conditions and in relation to angiotensin-converting enzyme inhibition. <u>24 March 2015</u> |

- F. Stringer Pharmacogenomics in drug development: implementation and application of PKPD model based approaches. 13 January 2015
- T. Sahota Pharmacology-based toxicity assessment – towards quantitative risk prediction in humans. 30 October 2014
- N. Snelder Towards predictive cardiovascular safety – a systems pharmacology approach. 25 juni 2014 (in collaboration with LAP&P Consultants BV)
- R. de Cock Towards a system-based pharmacology approach to predict developmental changes in renal drug clearance in children. 6 May 2014 (supported by a grant from TIPharma)
- J. Westerhout Prediction of brain target site concentrations on the basis of CSF pharmacokinetics. 6 March 2014 (supported by a grant from TIPharma)
- A. Taneja PKPD relationships and dose rationale in analgesic drug development – towards the prediction of target engagement. 20 November 2013 (supported by a grant from TIPharma)
- C. Wang Novel approaches to characterize developmental changes in pharmacokinetics across the human lifespan: application to the prediction of pharmacokinetics in children. 5 November 2013 (supported by a grant from TIPharma)
- A.S.Y. Chain Mind the gap – predicting cardiovascular safety in drug development. 09 October 2012. (supported by a grant from TIPharma)
- V. Pilla Reddy Translational PKPD modeling in schizophrenia – linking receptor occupancy of antipsychotics to efficacy and safety. 15 June 2012 (supported by a grant from TIPharma)
- M.G. Johnson Translational PKPD modeling in schizophrenia – predicting receptor occupancy of antipsychotics in man. 15 June 2012 (supported by a grant from TIPharma)
- I.H. Bartelink Individualization of drug exposure in pediatric hematopoietic stem cell transplantation. 19 April 2012 (supported by a grant from TIPharma)
- M. Cella Does size matter? Bridging and dose selection in paediatric trials 12 October 2011 (supported by a grant from Glaxo SmithKline, UK)
- J. Stevens Translational pharmacology of dopamine receptor agonists and antagonists. 22 September 2011 (supported by a grant from Pfizer, UK)
- R.R. Press Individualized dosing of calcineurin inhibitors in renal transplantation, April 13, 2011
- O. Ackaert Transdermal iontophoresis of dopaminergic (pro)drugs-From formulation to in vivo application, April 28, 2010 (Supported by grant STW LKG6507 from the Dutch Technology Foundation)
- P.G.M. Ravenstijn Systems Pharmacology and Blood-Brain Barrier Functionality in Parkinson's Disease, December 16, 2009 (Supported by a grant from Eli Lilly & Co)
- T.M. Post Disease system analysis between complexity and (over) simplification, December 1, 2009 (supported by a grant from TIPharma)

- A.E. Muller Population pharmacokinetics of antibiotics to prevent group B streptococcal disease: from mother to neonate, February 11, 2009 (Supported by a grant from the Nuts Ohra Foundation)
- T.J. van Steeg The ‘free drug hypothesis’: Fact or fiction? November 26, 2008 (Supported by a grant of Pfizer).
- D.R.H. Huntjens Beyond relief: biomarkers of the anti-inflammatory effect and dose selection of COX inhibitors in early drug development. November 18, 2008 (Supported by a grant of GlaxoSmithKline, UK)
- L.C. Liefwaard Pharmacoresistance in epilepsy: Modelling and prediction of disease progression. September 17, 2008 (Supported by a grant of Epilepsy Clinics Foundation in the Netherlands, SEIN)
- G.W.E. Santen To fail or not to fail - Clinical trials in depression, September 10, 2008. (Supported by a grant of GlaxoSmithKline, UK)
- M.Y.M. Peeters Population pharmacokinetic/pharmacodynamic analysis of propofol in children and long-term intensive care patients November 28, 2007 (Collaborative project with the Department of Clinical Pharmacy, St. Antonius Ziekenhuis, Nieuwegein).
- A. Yassen Mechanism-based pharmacokinetic-pharmacodynamic modelling of (synthetic) opiates: Buprenorphine versus fentanyl. October 24, 2007 (*cum laude*) (Supported by a grant of Grünenthal GmbH, Germany).
- D. Groenendaal Pharmacokinetic-Pharmacodynamic modelling of the anti-nociceptive response of (synthetic) opiates September 18, 2007 (Supported by a grant from GlaxoSmithKline, UK).
- M. Geldof Mechanism-based pharmacokinetic-pharmacodynamic modelling of neurotransmitter re-uptake inhibitors June 6, 2007 (Supported by a grant from Johnson & Johnson, Belgium)
- H.J. Maas Integration of disease progression, compliance and placebo effect in the characterisation of the therapeutic response to anti-migraine therapy. June 5, 2007 (Supported by a grant from GlaxoSmithKline, UK).
- A.K. Nugroho Transdermal iontophoretic delivery of dopamine agonists: *In Vitro - In Vivo* Correlation Based on Novel Compartmental Modeling. May 11, 2005 (Supported by QUE project Batch III year 2000-2004, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia)
- C.C. Visser The transferrin receptor at the blood-brain barrier: exploring the possibilities for brain drug delivery. January 18, 2005 (Supported by a grant from the New Drug Research Foundation, the Netherlands)
- E.L. Swart Population pharmacokinetics and pharmacodynamics of midazolam and lorazepam in critically ill intensive care patients May 13, 2004 (Collaborative project with the Department of Pharmacy, Academisch Ziekenhuis Vrije Universiteit, Amsterdam)
- D.M. Jonker Pharmacodynamic Analysis of Anti-epileptic Drug-drug Interactions *In Vivo*. November 18, 2003 (Supported by a grant from the Netherlands Epilepsy Foundation, Houten, the Netherlands)

- M.P. Schaddelee Adenosine A₁ receptor agonists. Blood-brain Barrier Transport and PK/PD Correlations in Neuropathic Pain. November 12, 2003 (Supported by a grant from GlaxoSmithKline, UK)
- S.A.G. Visser Mechanism-based Pharmacokinetic-Pharmacodynamic Modeling of the GABA_A Receptor Response *In Vivo*, June 10, 2003 (*cum laude*)
- T.J.H. Bueters Treatment of Organophosphate Poisoning with Adenosine A₁ Receptor Agonists. June 5, 2003 (Collaborative project with the TNO Prins Maurits Laboratory, Rijswijk)
- G.L. Li Transdermal Iontophoretic Delivery of R-apomorphine for the Treatment of Patients with Parkinson's Disease, May 14, 2003 (Supported by a grant from the Princess Beatrix Foundation, The Hague)
- K.P. Zuideveld Mechanism-based Pharmacokinetic-Pharmacodynamic Modelling: application to 5-HT_{1A} receptor mediated responses. September 5, 2002 (*cum laude*)
- C.A.J. Knibbe Pharmacokinetics, Pharmacodynamics and Safety of Different Propofol Formulations. Comparative Pharmacology in Rats, Surgical Patients, Intensive Care Patients and Children, January 16, 2002 (Collaborative project with the Department of Clinical Pharmacy, St. Antonius Ziekenhuis, Nieuwegein),
- A. Cleton: Mechanism-based modelling of functional adaptation, applied to anticonvulsant drug action. October 18, 2000 (Supported by grant 900-549-132 of the Netherlands Science Foundation),
- C.J.J.G. Bol: Concepts and Modeling of Synergistic Pharmacodynamic Drug-Drug Interactions: Application to Dexmedetomidine in Anesthesia, June 23, 1999 (Collaborative project with the Department of Anesthesia, Stanford University Medical School, U.S.A.),
- O.E. Della Pasqua: Preclinical Pharmacokinetic-Pharmacodynamic Modelling of the Anticonvulsant effect of Antiepileptic Drugs. October 15, 1998
- L. Tuk: *In vivo* Modelling of Mechanisms of Receptor Mediated Pharmacological Responses, October 8, 1998.
- R. van der Geest: PK/PD Based Drug Delivery System Design: Iontophoretic Delivery of Apomorphine in Parkinson's Disease, March 25, 1998.
- E. Snoeck Mechanism-Based Pharmacokinetic-Pharmacodynamic Modelling of Specific Target Site Binding to Red Blood Cells: Application to the development of Draflazine, February 19, 1998 (Janssen Research Foundation, Beerse, Belgium)
- E.A. van Schaick: Selectivity of Adenosine Receptor Agonists *In Vivo*. Assessment of Pharmacokinetic-Pharmacodynamic Correlations, December 16, 1997 (Supported by a grant of GlaxoSmithKline, UK).
- E.H. Cox: Preclinical Pharmacokinetic-Pharmacodynamic Relationships of Synthetic Opioids, October 8, 1997

- A.A.T.M.M. Vinks Strategies for Pharmacokinetic Optimization of Continuous Infusion Therapy of Ceftazidime and Aztreonam in Patients with Cystic Fibrosis, November 5, 1996 (Central Hospital Pharmacy, The Hague).
- R.A.A. Mathôt: Preclinical Pharmacokinetic-Pharmacodynamic Modelling of the Cardiovascular Effects of Adenosine Receptor Ligands, May 31, 1995.
- E.C.M. de Lange: Characterization of Drug Transport across the Blood-Brain-Barrier: Application of Intracerebral Microdialysis (Supported in part by grant IKW 88-6 of The Netherlands Cancer Research Foundation), December 9, 1993.
- A. Hoogerkamp: Pharmacokinetic-Pharmacodynamic Modelling with Antiepileptic Drugs (Supported by grant CLEO-A79 of The Netherlands Epilepsy Research Foundation), December 15, 1992.
- A.M. Stijnen: The Influence of Ageing on the Pharmacodynamics of Sedative and Anticonvulsant Drugs December 12, 1991 (Supported by grant 900-521-102 of The Netherlands Science Foundation),.
- J.W. Mandema: EEG Effect Measures and Relationships between Pharmacokinetics and Pharmacodynamics of Psychotropic Drugs September 18, 1991 (*cum laude*). (Supported by grant 900-521-106 of The Netherlands Science Foundation),
- A. de Boer: Drug Interaction Studies with Anticoagulant, Anti-platelet and Thrombolytic Drugs in Healthy Subjects June 14, 1990 (Supported by a grant from Organon International, The Netherlands)
- J.B.M.M. van Bree: Drug Transport across the Blood-Brain-Barrier: Characterization by *In Vitro* and *In Vivo* Strategies, June 6, 1990.
- J. Verhoeven: Controlled Drug Release with Polymers, June 7, 1989
- J. Dingemanse: Pharmacokinetic-Pharmacodynamic Modelling of Drug Effects on the Central Nervous System, April 20, 1988

Foreign Ph.D. Committees:

- B. Laurysens: Concentration and electroencephalogram effects of endogenous GABAergic neuroactive steroids (Supervisor: Prof. D. Greenblatt), Tufts University, Boston, USA, May 2000.
- M. Wakelkamp: Pharmacokinetic/pharmacodynamic Modelling of Furosemide-induced Diuresis in Man (Supervisor: Prof. G. Alvan), Karolinska Institute, Stockholm, Sweden, September, 1997.
- M. Ekblom: Studies on the Pharmacodynamics of Morphine and Morphine-6-Glucuronide in the Rat (Supervisor: Prof. L.K. Paalzow), Uppsala, Sweden, September 2, 1992.
- M. Sunzel: Potential Time Dependences in the Pharmacokinetics and Pharmacodynamics of the Benzodiazepine Midazolam (Supervisor: Prof. L.K. Paalzow), Uppsala, Sweden, December 8, 1989.

POST-DOCTORAL FELLOWS

A. Tanega	2013 - 2016
J. Berkhout	2013 - 2015
J. Duong	2013 - 2015
D. Teutonico	2010 – 2012 (supported by TIPharma)
F. Masumba	2010 – 2012 (supported by TIPharma)
S. Schmidt	2009 – 2012 (supported by TIPharma)
M. Kozielska	2007 – 2012 (supported by TIPharma)
Y. Tagawa	2004 – 2006 (supported by a grant from Takeda Ltd, Japan)
G. Bender	2003 – 2007 (supported by a grant from Pfizer Ltd, UK)
L. Franciosi	2003 – 2006 (supported by a grant from Glaxo Smith Kline, UK)
M. Garrido	1997 – 1999
P.H. van der Graaf	1996 – 1999
S. Appel	1992 – 1994 (supported by a grant from Novartis, Switzerland)
C. Hoyo-Vadillo	1989 – 1991
M. Sunzel	1990 – 1991

PUBLICATIONS

Full papers in scientific journals

1. J.M. Brussee, E.H.J. Krekels, E.A.M. Calvier et al., A pediatric covariate function for CYP3A-mediated midazolam clearance can scale selected CYP3A substrates in children
AAPS Journal 11: ... - (2019)
2. J.P. Mochel, C.H. Teng, M. Peyrou et al., Sacubitril/valsartan (LCZ696)
Europ. J. Pharm. Sci. 128: 103 – 111 (2019)
3. H.J. Blusse van Oud Alblas, M.J.E. Brill, M.Y.M. Peeters et al., Population pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery, with intra-operative wake-up test: a study using bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints
BMC Anesthesiology 19: ...-... (2019)
4. W.E. de Witte, M. Danhof, P.H. van der Graaf et al., The implications of target saturation for the use of the target residence time.
Nature Reviews Drug Discovery 18: ... - ... (2019)
5. M. Danhof, K. Klein, P.J. Stolk et al., The future of drug development: the paradigm-shift towards systems therapeutics
Drug Discovery Today 23: 1990-1995 (2018)
6. W.E. de Witte, V. Rottschäfer, M. Danhof, P.H. van der Graaf, L.A. Peletier, E.C.M. de Lange: Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models.
J Pharmacokinetic Pharmacodyn. 45(4):621-635 (2018).
7. W.E.A de Witte, J.W Vresfelt, M. Kuzikov et al., In vitro and in silico analysis of the effects of D-2 receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations.
Br. J. Pharmacol. 175: 4121-4136(2018)

8. S.C. van Dijkman, N.C.B. de Jager, W.M. Rauwé, M. Danhof, O. Della Pasqua. Correction to: Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials. Clin Pharmacokinet. 57(8):1055-1056 (2018).
9. E.M.T. van Maanen, T.J. van Steeg, M.J. Ahsman, M.S. Michener, M.J. Savage, M.E. Kennedy, H.J. Kleijn, J. Stone, M. Danhof: Extending a Systems Model of the APP Pathway: Separation of β - and γ -Secretase Sequential Cleavage Steps of APP. J Pharmacol Exp Ther. 2018 Jun;365(3):507-518.
10. E.A. Calvier, E.H.J. Krekels, H. Yu, P.A. Väitalo, T.N. Johnson, A. Rostami-Hodjegan, D. Tibboel, P.H. van der Graaf, M. Danhof, C.A.J. Knibbe: Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments. CPT Pharmacometrics Syst Pharmacol. 2018 Mar;7(3):175-185.
11. S.C. van Dijkman, N.C.B. de Jager, W.M. Rauwé, M. Danhof, O. Della Pasqua: Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials. Clin Pharmacokinet. 57(8):1039-1053 (2018).
12. A. Taneja, A. Vermeulen, D.R. Huntjens, M. Danhof, E.C.M. de Lange, J.H. Proost : Modeling of prolactin response following dopamine D2 receptor antagonists in rats: can it be translated to clinical dosing? Pharmacol Res Perspect. 2017 Dec;5(6).
13. A.H.C. Vlot, W.E. de Witte, M. Danhof, P.H. van der Graaf, van Westen GJP, E.C.M. de Lange: Target and Tissue Selectivity Prediction by Integrated Mechanistic Pharmacokinetic-Target Binding and Quantitative Structure Activity Modeling. AAPS J. 2017 Dec 4;20(1):1
14. Y. Yamamoto, P.A. Väitalo, Y.C. Wong, D.R. Huntjens, J.H. Proost , A. Vermeulen, W. Krauwinkel, M.W. Beukers, H. Kokki, M. Kokki, M. Danhof, J.G. van Hasselt C, E.C.M. de Lange: Prediction of human CNS pharmacokinetics using a physiologically based pharmacokinetic modeling approach. Eur J Pharm Sci. 2018 Jan 15;112:168-179.
15. A. Taneja, O. Della Pasqua, M. Danhof: Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm. Eur J Clin Pharmacol. 2017 Oct;73(10):1219-1236.
16. Y. Yamamoto, P.A. Väitalo, D.R. Huntjens, J.H. Proost , A. Vermeulen, W. Krauwinkel, M.W. Beukers, D.J. van den Berg, R. Hartman, Y.C. Wong, M. Danhof, J.G. van Hasselt, E.C.M. de Lange: Predicting Drug Concentration-Time Profiles in Multiple CNS Compartments Using a Comprehensive Physiologically-Based Pharmacokinetic Model. CPT Pharmacometrics Syst Pharmacol. 2017 Nov;6(11):765-777.
17. S.C. van Dijkman, W.M. Rauwé, M. Danhof, O. Della Pasqua: Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children. Br J Clin Pharmacol. 2018 Jan;84(1):97-111.
18. S.C. van Dijkman, Wicha SG, M. Danhof, O. Della Pasqua: Individualized Dosing Algorithms and Therapeutic Monitoring for Antiepileptic Drugs. Clin Pharmacol Ther. 2018 Apr;103(4):663-673.
- 13 V. Dubois, M. Danhof, O. Della Pasqua: Characterizing QT interval prolongation in early clinical development: a case study with methadone. Pharmacol Res Perspect. 2017 Jan 24;5(1)

14. Y. Yamamoto, M. Danhof, E.C.M. de Lange: Erratum to: Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations. AAPS J. 2017 Jul;19(4):1249-1252.
15. Y. Yamamoto, M. Danhof, E.C.M. de Lange: Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations. AAPS J. 2017 Jul;19(4):891-909.
16. V. Gotta, Z. Yu, F. Cools, K. van Ammel, D.J. Gallacher, S.A. Visser, F. Sannajust, P. Morisette, M. Danhof, P.H. van der Graaf: Application of a systems pharmacology model for translational prediction of hERG-mediated QTc prolongation. Pharmacol Res Perspect. 2016 Nov 17;4(6):e00270.
17. C. Piana, M. Danhof, O. Della Pasqua: Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV. Expert Opin Drug Metab Toxicol. 2017 May;13(5):497-511..
18. N. Snelder, B.A. Ploeger, O. Luttringer, D.F. Rigel, R.L. Webb, D. Feldman, F. Fu, M. Beil, L. Jin, D.R. Stanski, M. Danhof: Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach. J Pharmacol Exp Ther. 2017 Feb;360(2):356-367.
19. J. Berkhout, J.A. Stone, K.M. Verhamme, M. Danhof, T.M. Post: Disease Systems Analysis of Bone Mineral Density and Bone Turnover Markers in Response to Alendronate, Placebo, and Washout in Postmenopausal Women. CPT Pharmacometrics Syst Pharmacol. 2016 Dec;5(12):656-664.
20. Y. Yamamoto, P.A. Väitalo, D.J. van den Berg, R. Hartman, W. van den Brink, Y.C. Wong, D.R. Huntjens, J.H. Proost, A. Vermeulen, W. Krauwinkel, S. Bakshi, V. Aranzana-Climent, S. Marchand, C. Dahyot-Fizelier, W. Couet, M. Danhof, J.G. van Hasselt, E.C. de Lange: A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations. Pharm Res. 2017 Feb;34(2):333-351.
21. V. Dubois, G. Smania, H. Yu, R. Graf, A.S. Chain, M. Danhof, O. Della Pasqua: Cardiovascular Safety Project Team; TI Pharma PKPD Platform. Translating QT interval prolongation from conscious dogs to humans. Br J Clin Pharmacol. 2017 Feb;83(2):349-362.
22. J.K. Duong, W. de Winter, S. Choy, N. Plock, H. Naik, W. Krauwinkel, S.A. Visser, K.M. Verhamme, M.C. Sturkenboom, B.H. Stricker, M. Danhof: The variability in betacell function in placebo-treated subjects with type 2 diabetes: application of the weight-HbA1c-insulin-glucose (WHIG) model. Br J Clin Pharmacol. 2017 Mar;83(3):487-497.
23. A. Taneja, A. Vermeulen, D.R. Huntjens, M. Danhof, E.C. de Lange, J.H. Proost : Summary data of potency and parameter information from semi-mechanistic PKPD modeling of prolactin release following administration of the dopamine D2 receptor antagonists risperidone, paliperidone and remoxipride in rats. Data Brief. 2016 Aug 6;8:1433-7.
24. E.A. Calvier, E.H. Krekels, P.A. Väitalo, A. Rostami-Hodjegan, D. Tibboel, M. Danhof, C.A. Knibbe: Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade? Clin Pharmacokinet. 2017 Mar;56(3):273-285.
25. L. Kervezee, V. Gotta, J. Stevens, W. Birkhoff, I. Kamerling, M. Danhof, J.H. Meijer, J. Burggraaf: Levofloxacin-Induced QTc Prolongation Depends on the Time of Drug Administration. CPT Pharmacometrics Syst Pharmacol. 2016 Sep;5(9):466-74.

26. S.C. van Dijkman, R. Alvarez-Jimenez, M. Danhof, O. Della Pasqua: Pharmacotherapy in pediatric epilepsy: from trial and error to rational drug and dose selection - a long way to go. Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1143-56.
27. V. Dubois, E.Casarotto, M. Danhof, O. Della Pasqua: Pharmacokinetic-pharmacodynamic modelling of drug-induced QTc interval prolongation in man: prediction from in vitro human ether-à-go-go-related gene binding and functional inhibition assays and conscious dog studies. Br J Pharmacol. 2016 Oct;173(19):2819-32.
28. S. Bakshi, E.C. de Lange, P.H. van der Graaf, M. Danhof, L.A. Peletier: Understanding the Behavior of Systems Pharmacology Models Using Mathematical Analysis of Differential Equations: Prolactin Modeling as a Case Study. CPT Pharmacometrics Syst Pharmacol. 2016 Jul;5(7):339-51.
29. A. Taneja, A. Vermeulen, D.R. Huntjens, M. Danhof, E.C.M. de Lange, J.H. Proost : A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats. Eur J Pharmacol. 2016 Oct 15;789:202-214.
30. W.E. de Witte, M. Danhof, P.H. van der Graaf, E.C.M. de Lange: In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant. Trends Pharmacol Sci. 2016 Oct;37(10):831-842.
31. D.J. Moes, R.R. Press, O. Ackaert, B.A. Ploeger, F.J. Bemelman, C. Diack, J.A. Wessels, T. van der Straaten, M. Danhof, J.S. Sanders, J.J. Homan van der Heide, H.J. Guchelaar, J.W. de Fijter: Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients. Br J Clin Pharmacol. 2016 Jul;82(1):227-37.
32. M. Danhof: Systems pharmacology - Towards the modeling of network interactions. Eur J Pharm Sci. 2016 Oct 30;94:4-14.
33. T. Sahota, M. Danhof, O. Della Pasqua: Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans. Mutagenesis. 2016 May;31(3):359-74.
34. M. Johnson, M. Kozielska, V. Pilla Reddy, A. Vermeulen, H.A. Barton, S. Grimwood, R. de Greef, G.M. Groothuis , M. Danhof, J.H. Proost : Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D₂ Receptor Occupancy. Pharm Res. 2016 May;33(5):1305-6.
35. J.G. van Hasselt, M.L. Rizk, M. Lala, C. Chavez-Eng, S.A. Visser, T. Kerbusch, M. Danhof, G. Rao, P.H. van der Graaf: Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid. Br J Clin Pharmacol. 2016 Jun;81(6):1113-23.
36. M.J. Brill, P.A. Väliatalo, A.S. Darwich, B. van Ramshorst, H.P. van Dongen, A. Rostami-Hodjegan, M. Danhof, C.A. Knibbe: Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patients. CPT Pharmacometrics Syst Pharmacol. 2016 Jan;5(1):20-30.
37. E.M. van Maanen, T.J. van Steeg, M.S. Michener, M.J. Savage, M.E. Kennedy, H.J. Kleijn, J.A. Stone, M. Danhof: Systems Pharmacology Analysis of the Amyloid Cascade after β -Secretase Inhibition Enables the Identification of an A β 42 Oligomer Pool. J Pharmacol Exp Ther. 2016 Apr;357(1):205-16.

38. F. Bellanti, V.L. Di Iorio, M. Danhof, O. Della Pasqua: Sampling Optimization in Pharmacokinetic Bridging Studies: Example of the Use of Deferiprone in Children With β -Thalassemia. J Clin Pharmacol. 2016 Sep;56(9):1094-103.
39. M. Johnson, M. Kozielska, V. Pilla Reddy, A. Vermeulen, H.A. Barton, S. Grimwood, R. de Greef, G.M. Groothuis, M. Danhof, J.H. Proost : Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy. Pharm Res. Apr;33(4):1003-17. (2016)
40. P.A. Välitälo, K. Griffioen, M.L. Rizk, S.A. Visser, M. Danhof, G. Rao, P.H. van der Graaf, J.G. van Hasselt : Structure-Based Prediction of Anti-infective Drug Concentrations in the Human Lung Epithelial Lining Fluid. Pharm Res. Apr;33(4):856-67. (2016)
41. F. Bellanti, G.C. Del Vecchio, M.C. Putti, C. Cosmi, I. Fotzi, S.D. Bakshi, M. Danhof, O. Della Pasqua: Model-Based Optimisation of Deferoxamine Chelation Therapy. Pharm Res. Feb;33(2):498-509. (2016)
42. V. Dubois, W.E. de Witte, S.A. Visser, M. Danhof, O. Della Pasqua; Cardiovascular Safety Project Team; TI Pharma PKPD Platform: Assessment of Interspecies Differences in Drug-Induced QTc Interval Prolongation in Cynomolgus Monkeys, Dogs and Humans. Pharm Res. 2016
43. W.E. de Witte, Y.C. Wong, I. Nederpelt, L.H. Heitman, M. Danhof, P.H. van der Graaf, R.A. Gilissen, E.C. de Lange: Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients. Expert Opin Drug Discov.;11(1):45-63. (2016)
44. J. Berkhout, J.A. Stone, K.M. Verhamme, B.H. Stricker, M.C. Sturkenboom, M. Danhof, T.M. Post: Application of a Systems Pharmacology-Based Placebo Population Model to Analyze Long-Term Data of Postmenopausal Osteoporosis. CPT Pharmacometrics Syst Pharmacol. Sep;4(9):516-26. (2015)
45. J.P. Mochel, M. Danhof: Chronobiology and Pharmacologic Modulation of the ReninAngiotensin-Aldosterone System in Dogs: What Have We Learned? Rev Physiol Biochem Pharmacol.;169:43-69. (2015)
46. A. Taneja, S.P. Oosterholt, M. Danhof, O. Della Pasqua: Biomarker exposure-response relationships as the basis for rational dose selection: Lessons from a simulation exercise using a selective COX-2 inhibitor. J Clin Pharmacol. May;56(5):609-21. (2016)
47. M. Danhof: Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models. J Pharmacokinet Pharmacodyn. Oct;42(5):447-62. (2015)
48. A. Smits, R.F. de Cock , K. Allegaert, S. Vanhaesebrouck, M. Danhof, C.A. Knibbe: Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice. Antimicrob Agents Chemother. Oct;59(10):6344-51. (2015)
49. E.H. Krekels, S. van Ham, K. Allegaert, J. de Hoon, D. Tibboel, M. Danhof, C.A. Knibbe: Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants. Eur J Clin Pharmacol. Sep;71(9):1075-82. (2015)
50. V. Gotta, F. Cools, K. van Ammel, D.J. Gallacher, S.A. Visser, F. Sannajust, P. Morissette, M. Danhof, P.H. van der Graaf: Inter-study variability of preclinical in vivo safety studies and translational exposure-QTc relationships--a PKPD meta-analysis. Br J Pharmacol. Sep;172(17):4364-79. (2015)

51. D. Teutonico, F. Musuamba, J.H. Maas, A. Facius, S. Yang, M. Danhof, O. Della Pasqua: Generating Virtual Patients by Multivariate and Discrete Re-Sampling Techniques.
Pharm Res. Oct;32(10):3228-37. (2015)
52. A. Strougo, A. Yassen, M. Danhof, J.I. Freijer: Response to letter to the editor from Dr. Mahmood: Original publication: "Predicting the 'first dose in children' of CYP3Ametabolized drugs: evaluation of scaling approaches and insights into the CYP3A7CYP3A4 switch at young ages".
J Clin Pharmacol. Jun;55(6):721. (2015)
53. F. Bellanti, R.C. van Wijk, M. Danhof, O. Della Pasqua: Integration of PKPD relationships into benefit-risk analysis.
Br J Clin Pharmacol. Nov;80(5):979-91. 2015
54. T. Sahota, I. Sanderson, M. Danhof, O. Della Pasqua: Model-based prediction of the acute and long-term safety profile of naproxen in rats.
Br J Pharmacol. Aug;172(15):3861-74. (2015)
55. T. Sahota, M. Danhof, O. Della Pasqua: The impact of composite AUC estimates on the prediction of systemic exposure in toxicology experiments.
J Pharmacokinet Pharmacodyn. Jun;42(3):251-61. (2015)
56. V. Gotta, F. Cools, K. van Ammel, D.J. Gallacher, S.A. Visser, F. Sannajust, P. Morisette, M. Danhof, P.H. van der Graaf: Sensitivity of pharmacokinetic-pharmacodynamic analysis for detecting small magnitudes of QTc prolongation in preclinical safety testing.
J Pharmacol Toxicol Methods. Mar-Apr;72:1-10. (2015)
57. F. Stringer, J. DeJongh, K. Enya, E. Koumura, M. Danhof, K. Kaku: Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.
Diabetes Technol Ther. Mar;17(3):215-23. (2015)
58. J.P. Mochel, M. Fink, M. Peyrou, A. Soubret, J.M. Giraudel, M. Danhof: Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs.
Pharm Res. Jun;32(6):1931-46. (2015)
59. C.A. Knibbe, M.J. Brill, A. van Rongen, J. Diepstraten, P.H. van der Graaf, M. Danhof: Drug disposition in obesity: toward evidence-based dosing.
Annu Rev Pharmacol Toxicol.;55:149-67. (2015)
60. K. Romero, V. Sinha, S. Allerheiligen, M. Danhof, J. Pinheiro, N. Kruhlak, Y. Wang, S.J. Wang, JM Sauer, J.F. Marier, B. Corrigan, J. Rogers, H.J. Lambers Heerspink, T. Gumbo, P. Vis, P. Watkins, T. Morrison, W. Gillespie, M.F. Gordon, D. Stephenson, D. Hanna, M. Pfister, R. Lalonde, T. Colatsky: Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop.
J Pharmacokinet Pharmacodyn. Dec;41(6):545-52. (2014)
61. F.T. Musuamba, D. Teutonico, J.H. Maas, A. Facius, S. Yang, M. Danhof, O. Della Pasqua: Prediction of disease progression, treatment response and dropout in chronic obstructive pulmonary disease (COPD).
Pharm Res. Feb;32(2):617-27. (2015)
62. V. Dubois, H. Yu, M. Danhof, O. Della Pasqua; Cardiovascular Safety Project Team and TI Pharma PKPD Platform: Model-based evaluation of drug-induced QTc prolongation for compounds in early development.
Br J Clin Pharmacol. Jan;79(1):148-61. (2015)

63. F. Bellanti, M. Danhof, O. Della Pasqua: Population pharmacokinetics of deferiprone in healthy subjects.
Br J Clin Pharmacol. Dec;78(6):1397-406. (2014)
64. N. Snelder, B.A. Ploeger, O. Luttringer, D.R. Stanski, M. Danhof: Translational pharmacokinetic modeling of fingolimod (FTY720) as a paradigm compound subject to sphingosine kinase-mediated phosphorylation.
Drug Metab Dispos. 2014 Sep;42(9):1367-78. (2014)
65. N. Snelder, B.A. Ploeger, O. Luttringer, D.F. Rigel, F. Fu, M. Beil, D.R. Stanski, M. Danhof: Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling.
Br J Pharmacol. Nov;171(22):5076-92. (2014)
66. M. Johnson, M. Kozielska, V. Pilla Reddy, A. Vermeulen, H.A. Barton, S. Grimwood, R. de Greef, G.M. Groothuis, M. Danhof, J.H. Proost : Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach.
Pharm Res. Oct;31(10):2605-17. (2014)
67. R.F. de Cock, K. Allegaert, J.M. Brussee, C.M. Sherwin, H. Mulla, M. de Hoog, J.N. van den Anker, M. Danhof, C.A. Knibbe: Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration.
Pharm Res. Oct;31(10):2643-54.(2014).
68. A. Strougo, A. Yassen, C. Monnereau, M. Danhof, J.I. Freijer: Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages.
J Clin Pharmacol. Sep;54(9):1006-15. (2014).
69. T. Sahota, I. Sanderson, M. Danhof, O. Della Pasqua: Model-based analysis of thromboxane B₂ and prostaglandin E₂ as biomarkers in the safety evaluation of naproxen.
Toxicol Appl Pharmacol. 2014 Aug 1;278(3):209-19. (2014)
70. J.P. Mochel, M. Fink, C. Bon, M. Peyrou, B. Bieth, C. Desevaux, M. Deurinck, J.M. Giraudel, M. Danhof: Influence of feeding schedules on the chronobiology of renin activity, urinary electrolytes and blood pressure in dogs.
Chronobiol Int. Jun;31(5):715-30. (2014)
71. E.H. Krekels, D. Tibboel, S.N. de Wildt, I. Ceelie, A. Dahan, M. van Dijk, M. Danhof, C.A. Knibbe: Evidence-based morphine dosing for postoperative neonates and infants.
Clin Pharmacokinet. 2014 Jun;53(6):553-63.
72. R.F. de Cock, A. Smits, K. Allegaert, J. de Hoon, V. Saegeman, M. Danhof, C.A. Knibbe: Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates.
J Antimicrob Chemother. May;69(5):1330-8. (2014)
73. J. Westerhout, D.J. van den Berg, R. Hartman, M. Danhof, E.C. de Lange: Prediction of methotrexate CNS distribution in different species - influence of disease conditions.
Eur J Pharm Sci. Jun 16;57:11-24. (2014)
74. C. Piana, M. Danhof, O. Della Pasqua: Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research.
Br J Clin Pharmacol. Jul;78(1):145-57. (2014)
75. C. Wang, K. Allegaert, D. Tibboel, M. Danhof, C.D. van der Marel, R.A. Mathot, C.A. Knibbe: Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults.
J Clin Pharmacol. Jun;54(6):619-29. (2014)

76. R.F. de Cock, K. Allegaert, S. Vanhaesebrouck, J. de Hoon, R. Verbesselt, M. Danhof, C.A. Knibbe: Low but inducible contribution of renal elimination to clearance of propylene glycol in preterm and term neonates.
Ther Drug Monit. Jun;36(3):278-87. (2014)
77. F. Stringer, J. DeJongh, G. Scott, M. Danhof: A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar.
J Clin Pharmacol. Apr;54(4):453-61. (2014)
78. C. Piana, W. Zhao, K. Adkinson, D. Burger, E. Jacqz-Aigrain, M. Danhof, O. Della Pasqua: Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children.
Br J Clin Pharmacol. May;77(5):861-72. (2014)
79. C. Piana, W. Zhao, K. Adkinson, D. Burger, E. Jacqz-Aigrain, M. Danhof, O. Della Pasqua: A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children.
Br J Clin Pharmacol. May;77(5):852-60. (2014)
80. V. Pilla Reddy, M. Kozielska, M. Johnson, N. Mafirakureva, A. Vermeulen, J. Liu , R. de Greef, D. Rujescu, G.M. Groothuis, M. Danhof, J.H. Proost : Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale.
J Clin Psychopharmacol. Dec;33(6):731-9. (2013)
81. A. Taneja, I.F. Troconiz, M. Danhof, O. Della Pasqua; Neuropathic Pain Project of the PKPD Modelling Platform: Semi-mechanistic modelling of the analgesic effect of gabapentin in the formalin-induced rat model of experimental pain.
Pharm Res. Mar;31(3):593-606. (2014)
82. R.F. de Cock, K. Allegaert, C.M. Sherwin, E.I. Nielsen, M. de Hoog, J.N. van den Anker, M. Danhof, C.A. Knibbe: A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates.
Pharm Res. (2014)
83. A.S. Chain, M.C. Sturkenboom, M. Danhof, O. Della Pasqua: Establishing in vitro to clinical correlations in the evaluation of cardiovascular safety pharmacology.
Drug Discov Today Technol. Sep;10(3):e373-83. (2013)
84. J.P. Mochel, M. Fink, M. Peyrou, C. Desevaux, M. Deurinck, J.M. Giraudel, M. Danhof: Chronobiology of the renin-angiotensin-aldosterone system in dogs: relation to blood pressure and renal physiology.
Chronobiol Int. Nov;30(9):1144-59. (2013)
85. N. Snelder, B.A. Ploeger, O. Luttringer, D.F. Rigel, R.L. Webb, D. Feldman, F. Fu, M. Beil, L. Jin, D.R. Stanski, M. Danhof: PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats.
Br J Pharmacol. Aug;169(7):1510-24. 2013
86. S.A. Visser, E. Manolis, M. Danhof, T. Kerbusch: Modeling and simulation at the interface of nonclinical and early clinical drug development.
CPT Pharmacometrics Syst Pharmacol. Feb 27;2:e30. (2013)
87. C. Wang, K. Allegaert, M.Y. Peeters, D. Tibboel, M. Danhof, C.A. Knibbe: The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults.
Br J Clin Pharmacol. Jan;77(1):149-59. (2014)

88. C. Wang, S. Sadhavisvam, E.H. Krekels, A. Dahan, D. Tibboel, M. Danhof, A.A. Vinks, C.A. Knibbe: Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model. Clin Drug Investig. Jul;33(7):523-34. (2013)
89. A.S. Chain, J.P. Dieleman, C. van Noord, A. Hofman, B.H. Stricker, M. Danhof, M.C. Sturkenboom, O. Della Pasqua: Not-in-trial simulation I: Bridging cardiovascular risk from clinical trials to real-life conditions. Br J Clin Pharmacol. Dec;76(6):964-72. (2013)
90. C.A. Knibbe, D. Tibboel, S.N. de Wildt, M. de Hoog, Tjoeng MM, M. Danhof: [Individualized dosing guidelines for children]. Ned Tijdschr Geneesk. 157(16):A4214. Review. Dutch. (2013)
91. J. Westerhout, J. Smeets, M. Danhof, E.C. de Lange: The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid. J Pharmacokinet Pharmacodyn. Jun;40(3):327-42. 2013
92. I. Ince, S.N. de Wildt, C. Wang, M.Y. Peeters, J. Burggraaf, E. Jacqz-Aigrain, J.N. van den Anker, D. Tibboel, M. Danhof, C.A. Knibbe: A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults. Clin Pharmacokinet. 2013 Jul;52(7):555-65. (2013)
Erratum in: Clin Pharmacokinet. 2013 Jul;52(7):611. Wang, Chengueng [corrected to Wang, Chenguang].
93. V. Pilla Reddy, M. Kozielska, A.A. Suleiman, M. Johnson, A. Vermeulen, J. Liu, R. de Greef, G.M. Groothuis, M. Danhof, J.H. Proost : Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score. Schizophr Res. May;146(1-3):153-61. (2013)
94. V. Pilla Reddy, M. Kozielska, A.A. Suleiman, M. Johnson, A. Vermeulen, J. Liu, R. de Greef, G.M. Groothuis, M. Danhof, J.H. Proost : Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: the use of PANSS total score and clinical utility. Schizophr Res. May;146(1-3):144-52. (2013).
95. I. Ince, C.A. Knibbe, M. Danhof, S.N. de Wildt: Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations. Clin Pharmacokinet. 2013 May;52(5):333-45. Review. (2013)
96. F. Stringer, B.A. Ploeger, J. DeJongh, G. Scott, R. Urquhart, A. Karim, M. Danhof: Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar. J Clin Pharmacol. 53(3):256-63. (2013)
97. M. Kozielska, V. Pilla Reddy, M. Johnson, F. de Ridder, A. Vermeulen, J. Liu , G.M. Groothuis, M. Danhof, J.H. Proost: Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia. Schizophr Res. May;146(1-3):53-8. (2013)
98. A.S. Chain, V. Dubois, M. Danhof, M.C. Sturkenboom, O. Della Pasqua; Cardiovascular Safety Project Team, TI Pharma PKPD Platform: Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation. Br J Clin Pharmacol. Nov;76(5):708-24. (2013)
101. T.M. Post, S. Schmidt, L.A. Peletier, R. de Greef, T. Kerbusch, M. Danhof: Application of a mechanism-based disease systems model for osteoporosis to clinical

- data.
J Pharmacokinet Pharmacodyn. Apr;40(2):143-56. (2013)
102. A. Taneja, J. Nyberg, E.C. de Lange, M. Danhof, O. Della Pasqua: Application of ED optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain.
J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):673-81.
 103. A. Taneja, J. Nyberg, M. Danhof, O. Della Pasqua: Optimised protocol design for the screening of analgesic compounds in neuropathic pain.
J Pharmacokinet Pharmacodyn. 39(6):661-71. (2012)
 104. W. Zhao, C. Piana, M. Danhof, D. Burger, O. Della Pasqua, E. Jacqz-Aigrain: Population pharmacokinetics of abacavir in infants, toddlers and children.
Br J Clin Pharmacol. Jun;75(6):1525-35. (2013)
 105. I.H. Bartelink, S.V. Belitser, C.A. Knibbe, M. Danhof, A.J. de Pagter, T.C. Egberts, J.J. Boelens: Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children.
Biol Blood Marrow Transplant. Feb;19(2):305-13. (2013)
 106. R. Gaspar, B. Aksu, A. Cuine, M. Danhof, M.J. Takac, H.H. Linden, A. Link, E.M. Muchitsch, C.G. Wilson, P. Ohrngren, L. Dencker. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Eur J Pharm Sci. Dec 18;47(5):979-87. Epub 2012 Oct 6. (2012)
 107. E.H. Krekels, D. Tibboel, M. Danhof, C.A. Knibbe: Prediction of morphine clearance in the paediatric population : how accurate are the available pharmacokinetic models?
Clin Pharmacokinet. Nov;51(11):695-709. Review. (2012)
 108. I.H. Bartelink, C. van Kesteren, J.J. Boelens, T.C. Egberts, M.B. Bierings, G.D. Cuvelier, R.F. Wynn, M.A. Slatter, R. Chiesa, M. Danhof, C.A. Knibbe: Predictive performance of a busulfan pharmacokinetic model in children and young adults.
Ther Drug Monit. Oct;34(5):574-83. (2012)
 109. J. Stevens, B.A. Ploeger, M. Hammarlund-Udenaes, G. Osswald, P.H. van der Graaf, M. Danhof, E.C. de Lange: Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans.
J Pharmacokinet Pharmacodyn. Oct;39(5):463-77. Epub 2012 Jul 12. (2012)
 110. I. Ince, S.N. de Wildt, M.Y. Peeters, D.J. Murry, D. Tibboel, M. Danhof, C.A. Knibbe: Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years.
Ther. Drug Monit. 34: 381-389 (2012)
 111. F. Stringer, B.A. Ploeger, J. DeJongh, G. Scott, R. Urquhart, A. Karim, M. Danhof: Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar
J. Clin. Pharmacol. (2012) [Epub ahead of print]
 112. J. Westerhout, B. Ploeger, J. Smeets, M. Danhof, E.C. de Lange: Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats
AAPS J. 14: 543-553 (2012)
 113. J.P. Mochel, M. Peyrou, M. Fink, G. Strehlau, R. Mohamed, J.M. Giraudel, B. Ploeger, M. Danhof: capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs
J. Vet. Pharmacol. Ther. Apr;36(2):174-80 (2013)

114. R.F. de Cock, C.A. Knibbe, A. Kulo, J. de Hoon, R. Verbesselt, M. Danhof, K. Allegaert: Developmental pharmacokinetics of propylene glycol in preterm and term neonates.
Br. J. Clin. Pharmacol. Jan;75(1):162-71 (2013)
115. I.H. Bartelink, J.J. Boelens, R.G. Bredius, A.C. Egberts, C. Wang, M.B. Bierings, P.J. Shaw, C.E. Nath, G. Hempel, J. Zwaveling, M. Danhof, C.A. Knibbe: Body-weight dependent pharmacokinetics of busulfan in pediatric haematopoietic stem cell transplantation patients: towards individualized dosing.
Clin. Pharmacokinet. 51: 331-345 (2012)
116. E.H. Krekels, M. Danhof, D. Tibboel, C.A. Knibbe: Ontogeny of hepatic glucuronidation
Current Drug Metab. 13: 728-743 (2012)
117. A. Taneja, V.L. Di Iorio, M. Danhof, O. Della Pasqua: Translation of drug effects from experimental models of neuropathic pain and analgesia to humans
Drug Discov. Today. Aug;17(15-16):837-49 (2012)
118. M. Kozielska, M. Johnson, V. Pilla Reddy, A. Vermeulen, C. Li, S. Grimwood, R. de Greef, G.M. Groothuis, M. Danhof, J.H. Proost : Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT_{2A} receptor occupancy of risperidone and paliperidone in rats
Pharm Res. 29: 1932-1948 (2012)
119. V. Pilla Reddy, M. Kozielska, M. Johnson, A.A. Suleiman, A. Vermeulen, J. Liu, R. de Greef, G.M. Groothuis, M. Danhof, J.H. Proost : Modeling and simulation of the Positive and Negative Syndrome Scale (PANNS) time course and dropout hazard in placebo arms of schizophrenia clinical trials
Clin. Pharmacokinet. 51: 261-275 (2012).
120. M. Cella, M. Danhof, O. Della Pasqua: Bridging strategies for drug combinations in pediatric indications.
Clin. Pharmacol. Ther. 91: 726-733 (2012)
121. M. Cella, F. Klopogge, M. Danhof, O. Della Pasqua: Dosing rationale for fixed-dose combinations in children: shooting from the hip?
Clin. Pharmacol. Ther. 91: 718-725 (2012).
122. P.G. Ravenstijn, H.J. Drenth, M.J. O'Neill, M. Danhof, E.C. de Lange: Evaluation of blood-brain barrier transport and CNS drug metabolism in disease and control brain after intravenous L-DOPA in a unilateral model of Parkinson's disease.
Fluids Barriers CNS Feb 8;9:4 (2012)
123. A. Strougo, T. Eissing, A. Yassen, S. Willmann, M. Danhof, J.I. Freijer: First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development.
J. Pharmacokinet. Pharmacodyn. 39: 195-203 (2012)
124. M. Cella, C.A. Knibbe, S.N. de Wildt, J. van Gerven, M. Danhof, O. Della Pasqua: scaling pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models.
Br. J. Clin. Pharmacol. [Epub ahead of print]

125. C. Wang, M.Y. Peeters, K. Allegaert, H.J. Blussé van Oud-Alblas, E.H. Krekels, D. Tibboel, M. Danhof, C.A. Knibbe: A bodyweight-dependent allometric exponent for scaling clearance across the human life-span.
Pharm Res. 29: 1570-1581 (2012)
126. M. Cella, M. Danhof, O. Della Pasqua: Adaptive trials in paediatric development: dealing with heterogeneity and uncertainty in pharmacokinetic differences in children.
Br J Clin Pharmacol. 74: 346-353 (2012).
127. R.F. de Cock, K. Allegaert, M.F. Schreuder, C.M. Sherwin, M. de Hoog, J.N. van den Anker, M. Danhof, C.A. Knibbe: Maturation of the glomerular filtration rate in neonates as reflected by amikacin clearance.
Clin Pharmacokinet. 51:105-117 (2012)
128. A.S. Chain, K.M. Krudys, M. Danhof, O. Della Pasqua: Assessing the probability of drug-induced QTc-interval prolongation during clinical drug development.
Clin Pharmacol Ther. 90: 867-875 (2011)
129. S. Schmidt, T.M. Post, L.A. Peletier, M.A. Boroujerdi, M. Danhof: Coping with time scales in disease systems analysis: application to bone-remodeling.
J Pharmacokinet Pharmacodyn. 38:873-900 (2011)
130. S. van Kralingen, J. Diepstraten, M.Y. Peeters, V.H. Deneer, B. van Ramshorst, R.J. Wiezer, E.P. van Dongen, M. Danhof, C.A. Knibbe: Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients.
Clin Pharmacokinet. 50:739-750 (2011)
131. J. Stevens, B.A. Ploeger, P.H. van der Graaf, M. Danhof, E.C. de Lange: Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration.
Drug Metab Dispos. 39: 2275-2282 (2011)
132. V. Pilla Reddy, M. Kozielska, M. Johnson, A. Vermeulen, R. de Greef, J. Liu, G.M. Groothuis, M. Danhof, J.H. Proost : Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders
Clin Pharmacokinet. 50:429-450 (2011).
133. M. Johnson, M. Kozielska, V. Pilla Reddy, A. Vermeulen, C. Li, S. Grimwood, R. de Greef, G.M. Groothuis, M. Danhof, J.H. Proost : Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats
Pharm Res. 28: 2490-2504 (2011)
134. J. Westerhout, M. Danhof, E.C. de Lange: Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting
J Pharm Sci. 100:3577-3593 (2011)
135. M. Cella, W. Zhao, E. Jacqz-Aigrain, D. Burger, M. Danhof, O. Della Pasqua: Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations?
Br J Clin Pharmacol. 72: 454-464 (2011)
136. A. Strougo, A. Yassen, W. Krauwinkel, M. Danhof, J.I. Freijer: A semi-physiological model for prediction of the pharmacokinetics of drugs under liver and renal disease conditions
Drug Metab Dispos. 39:1278-1287 (2011)
137. C.A. Knibbe, M. Danhof: Individualized dosing regimens in children based on population PKPD modeling: are we ready for it?
Int J Pharm. 415:9-14 (2011)

138. G. Santen, E. van Zwet, P. Bettica, R.A. Gomeni, M. Danhof, O. Della Pasqua: From trial and error to trial simulation III: a framework for interim analysis in efficacy trials with antidepressant drugs
Clin Pharmacol Ther. 89:602-607 (2011)
139. O.W. Ackaert, J. de Graan, S. Shi, R. Vreeken, O.E. Della Pasqua, D. Dijkstra, B.H. Westerink, M. Danhof, J.A. Bouwstra: The pharmacokinetics and pharmacological effect of (S)-5-OH-DPAT following controlled delivery with transdermal iontophoresis.
J Pharm Sci. 100: 2996-3009 (2011)
140. E.H. Krekels, J.G. van Hasselt, D. Tibboel, M. Danhof, C.A. Knibbe: Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models.
Pharm Res. 28:797-811 (2011)
141. E.H. Krekels, J. DeJongh, R.A. van Lingen, C.D. van der Marel, I. Choonara, A.M. Lynn, M. Danhof, D. Tibboel, C.A. Knibbe: Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children.
Clin Pharmacokinet. 50:51-63 (2011)
142. C.A. Knibbe, E.H. Krekels, M. Danhof: Advances in paediatric pharmacokinetics.
Expert Opin Drug Metab Toxicol. 7:1-8 (2011).
143. M. Cella, C.A. Knibbe, M. Danhof, O. Della Pasqua: What is the right dose for children?
Br J Clin Pharmacol. 70(4):597-603 (2010)
144. K. Romero, B. Corrigan, C.W. Tornøe, J.V. Gobburu, M. Danhof, W.R. Gillespie, M.R. Gastonguay, B. Meibohm, H. Derendorf: Pharmacometrics as a discipline entering the industrialization phase: standards, automation, knowledge sharing and training are critical for future success.
J. Clin. Pharmacol. 50: 9S-19S (2010).
145. O.W. Ackaert, J. de Graan, R. Capancioni, D. Dijkstra, M. Danhof, J.A. Bouwstra: Transdermal iontophoretic delivery of a novel series of dopamine agonists in vitro: physicochemical considerations.
J Pharm Pharmacol. 62:709-720 (2010).
146. G. Bender, J.A. Florian Jr, S. Bramwell, M.J. Field, K.K. Tan, S. Marshall, J. DeJongh, R.R. Bies, M. Danhof: Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain.
J. Pharmacol. Exp. Ther. 334: 599-608 (2010).
147. R.R. Press, B.A. Ploeger, J. den Hartigh, T. van der Straaten, H. van Pelt, M. Danhof, H. de Fijter, H.J. Guchelaar: Explaining variability in ciclosporin exposure in adult kidney transplant recipients.
Europ. J. Clin. Pharmacol. 66: 579-590 (2010)
148. R.F. de Cock, C. Piana, E.H. Krekels, M. Danhof, K. Allegaert, C.A. Knibbe: The role of population PK-PD modelling in paediatric clinical research.
Europ. J. Clin. Pharmacol. 67: 5-16.
149. J. Stevens, D.J. van den Berg, S. de Ridder, H.A. Niederländer, P.H. van der Graaf, M. Danhof, E.C. de Lange: Online solid phase extraction with liquid chromatography-tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples.
J. Chromatogr. B 878: 969-975 (2010)

150. O.W. Ackaert, J. de Graan, R. Capancioni, O. Della Pasqua, D. Dijkstra, B.H. Westerink, M. Danhof, J.A. Bouwstra. The in vitro and in vivo evaluation of new synthesized prodrugs of 5-OH-DPAT for iontophoretic delivery. J Control Release. 15: 296-305 (2010).
151. M.Y. Peeters, K. Allegaert, H.J. Blussé van Oud-Alblas, M. Cella, D. Tibboel, M. Danhof, C.A. Knibbe. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin. Pharmacokinet. 49: 269-275 (2010)
150. A.E. Muller, J.W. Mouton, P.M. Oostvogel, P.J. Dörr, R.A. Voskuyl, J. DeJongh, E.A. Steegers, M. Danhof: The pharmacokinetics of clindamycin in pregnant women in the peripartum period. Antimicrob. Agents Chemother. (2010)
151. O. Della Pasqua, G. Santen, M. Danhof: The missing link between clinical endpoints and drug targets in depression. Trends Pharmacol Sci 31: 144-152 (2010)
152. M. Cella, F. Gorter de Vries, D. Burger, M. Danhof, O. Della Pasqua: A model-based approach to dose selection in early pediatric development. Clin Pharmacol Ther 87: 294 – 302 (2010)
153. T.M. Post, S.C. Cremers, T. Kerbusch, M. Danhof: Bone physiology, disease and treatment: towards disease system analysis in osteoporosis Clin pharmacokinet 49 (2) 89-118 (2010)
154. O.W. Ackaert, J. van Smeden, J. de Graan, D. Dijkstra, M. Danhof, J.A. Bouwstra: Mechanistic studies of the transdermal iontophoretic delivery of 5-OH-DPAT in vitro J Pharm Sci 99 (1) 275-285 (2010)
155. T.J. van Steeg, E.H. Krekels, J.I. Freijer, M. Danhof, E.C. de Lange: Effect of altered AGP plasma binding on heart rate changes by S(-) propranolol in rats using mechanism-based estimations of in vivo receptor affinity (K(B, vivo)) J Pharm Sci 99: 2511-2520 (2010)
156. D.R. Huntjens, D.J. Spalding, M. Danhof, O. Della Pasqua: Impact of chronic inflammation on the pharmacokinetic-pharmacodynamic relationship of naproxen Eur J Pain 14: e1-10 (2010)
157. G. Santen, J. Horrigan, M. Danhof, O. Della Pasqua: From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs Clin Pharmacol Ther 86 (3) 255-262 (2009)
158. G. Bender, J. Gosset, J. Florian, K. Tan, M. Field, S. Marshall, J. DeJongh, R. Bies, M. Danhof: Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: application of simulation to preclinical PK-PD study design Pharm Res (10) 2259-2269 (2009)
159. G. Santen, E. van Zwet, M. Danhof, O. Della Pasqua: From trial and error to trial simulation. Part 1: the importance of model-based drug development for antidepressant drugs Clin Pharmacol Ther 86 (3) 248-254 (2009)
160. C.A. Knibbe, E.H. Krekels, J.N. van den Anker, J. DeJongh, G. Santen, M. van Dijk, S.H. Simons, R.A. van Lingen, E.M. Jacqz-Aigrain, M. Danhof, D. Tibboel: Morphine glucuronidation in preterm neonates, infants and children younger than 3 years Clin Pharmacokinet 48 (6) 371-385 (2009)
161. R. Clinckers, I. Smolders, K. Vermoesen, Y. Michotte, M. Danhof, R. Voskuyl, O. Della Pasqua: Prediction of antiepileptic drug efficacy: the use of intracerebral

- microdialysis to monitor biophase concentrations
Expert Opin Drug Metab Toxicol (10) 1267-1277 (2009)
- 162 J. Stevens, E. Suidgeest, P.H. van der Graaf, M. Danhof, E.C. de Lange: A new minimal –stress freely-moving rat model for preclinical studies on intranasal administration of CNS drugs
Pharm Res (8) 1911-1917 (2009)
- 163 G. Santen, M. Danhof, O. Della Pasqua: Sensitivity of the Montgomery Asberg Depression Rating Scale to response and its consequences for the assessment of efficacy
J Psychiatr Res 43 (12) 1049-1056 (2009)
- 164 H. Maas, M. Danhof, O. Della Pasqua: Analysis of the relationship between age and treatment response in migraine
Cephalalgia. (7) 772-780(2009)
- 165 R.R. Press, B.A. Ploeger, J. den Hartigh, T. van der Straaten, J. van Pelt, M. Danhof, J.W. de Fijter, H.J. Guchelaar: Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients
The Drug Monit 31(2) 187-197 (2009)
- 166 B.A. Ploeger, P.H. Graaf, M. Danhof: Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling
Drug Metab Pharmacokinet 24 (1): 3-15 (2009)
- 167 A.E. Muller, P.M. Oostvogel, J. DeJongh, J.W. Mouton, E.A. Steegers, P.J. Door, M. Danhof, R.A. Voskuyl: Pharmacokinetics of amoxicillin in maternal, umbilical cord and neonatal serum
Antimicrob. Agents Chemother. 53 (4) 1574-1580 (2009)
- 168 T.J. van Steeg, V.B. Boralli, E.H. Krekels, P. Slijkerman, J.I. Freijer, M. Danhof, E.C. de Lange: Influence of plasma protein binding on pharmacodynamics: estimation of in vivo receptor affinities of net blockers using a new mechanism-based PK-PD modeling approach
J. Pharm Sci 98: 3816-3828 (2009)
- 169 B.A. Ploeger, J. Smeets, A. Strougo, H.J. Drenth, N. Houwing and M. Danhof: Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex
Anesthesiology 110: 95-105 (2009)
- 170 I. Ince, S.N. de Wildt, D. Tibboel, M. Danhof, C.A. Knibbe: Tailor-made drug treatment for children Creation of an infrastructure for datasharing and population PK-PD modeling.
Drug Discov Today 14 (5-6) 316-320(2009)
- 171 R. Verpoorte, D. Crommelin, M. Danhof, L.J. Gilissen, H. Schuitmaker, J. van der Greef, R.F. Witkamp: Commentary: "A systems view on the future of medicine: inspiration from Chinese medicine?"
J Ethnopharmacol 121: 479-481 (2009).
- 172 A.E. Muller, P.J. Dörr, J.W. Mouton, J. DeJongh, P.M. Oostvogel, E.A. Steegers, R.A. Voskuyl, M. Danhof: The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women.
Br J Clin Pharmacol 66(6) 866-874 (2008)
- 173 R. Clinckers, I. Smolders, Y. Michotte, G. Ebinger, M. Danhof, R.A. Voskuyl, O. Della Pasqua: Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain.
Br J Pharmacol 155 (7) 1127-1138 (2008)

- 174 D.R. Huntjens, D.J. Spalding, M. Danhof, O. Della Pasqua: Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo-oxygenase inhibitors.
Eur J Pain **13**(5) 448-457 (2009).
- 175 L.C. Liefwaard, B.A. Ploeger, C.F. Molthoff, H.W. de Jong, J. Dijkstra, L. van der Weerd, A.A. Lammertsma, M. Danhof, R.A. Voskuyl: Changes in GABA (A) receptor properties in amygdala kindled animals: In vivo studies using [(11)C]flumazenil and positron emission tomography.
Epilepsia **50**: 88-98 (2009).
- 176 J.H. Maas, N. Snelder, M. Danhof, O. Della Pasqua: Prediction of attack frequency in migraine treatment
Cephalalgia **28**: 847-855 (2008)
- 177 M. Geldof, J.I. Freijer, L. van Beijsterveldt, X. Langlois, M. Danhof: Pharmacokinetic-pharmacodynamic modelling of fluvoxamine 5-HT transporter occupancy in rat frontal cortex.
Br J Pharmacol **154**(6) 1369-1378 (2008)
- 178 D. Groenendaal, J.I. Freijer, A. Rosier, D. de Mik, G. Nicholls, A. Hersey, A.D. Ayrton, M. Danhof, E.C. de Lange: Pharmacokinetic-pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics.
Eur J Pharm Sci. **34** (2-3) 149-163 (2008)
- 179 M. Danhof, E.C. de Lange, O. Della Pasqua, B.A. Ploeger, R.A. Voskuyl: Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
Trends Pharmacol Sci. **29**(4) 186-191 (2008)
- 180 G. Santen, M. Danhof, O. Della Pasqua: Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model.
J Psychiatr Res. **42** (14) 1189-1197 (2008)
- 181 M. Geldhof, J.I. Freijer, L.A. Peletier, L. van Beijsterveldt, M. Danhof: Mechanistic model for the acute effect of fluvoxamine on 5-HT and 5-HIAA concentrations in rat frontal cortex.
Eur J Pharm Sci. **33**(3) 217-229 (2008)
- 182 G. Santen, R. Gomeni, M. Danhof, O. Della Pasqua: Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy.
J Psychiatr Res. **42** (12):1000-1009 (2008)
- 183 T.M. Post, J.I. Freijer, B.A. Ploeger, M. Danhof.: Extensions to the Visual Predictive Check to facilitate model performance evaluation.
J Pharmacokinet Pharmacodyn. **35** (2):185-202 (2008)
- 184 D.R. Huntjens, A. Strougo, A. Chain, A. Metcalf, S. Summerfield, D.J. Spalding, M. Danhof, O. Della Pasqua: Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats.
Br J Pharmacol. **153**(5):1072-1084 (2008)
- 185 A.E. Muller, J. DeJongh, P.M. Oostvogel, R.A. Voskuyl, P.J. Dörr, M. Danhof, J.W. Mouton: Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes.
Am J Obstet Gynecol.; **198**(1):108.e1-6. (2008)
- 186 J.H. Maas, M.A. Spruit, M. Danhof, O. Della Pasqua: Relevance of absorption rate and lag time to the onset of action in migraine.
Clin Pharmacokinet.; **47**(2)139-146. (2008)

- 187 A. Yassen, E. Olofsen, J. Kan, A. Dahan, M. Danhof: Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats.
Pharm Res.;25(1):183-193. (2008)
- 188 T.J. van Steeg, J.I. Freijer, M. Danhof, E.C. de Lange: Mechanism-based pharmacodynamic modeling of S(-)-Atenolol: Estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model.
J Pharmacol Exp Ther. 324 (3):1234-1242(2007)
- 189 M. Geldof, J.I. Freijer, L.A. Peletier, L. van Beijsterveldt, M. Danhof. Mechanistic model for the acute effect of fluvoxamine on 5-HT and 5-HIAA concentrations in rat frontal cortex.
Eur J Pharm Sci. 33 (3):217-229 (2007)
- 190 M.Y. Peeters, L.P. Aarts, F.A. Boom, L.J. Bras, D. Tibboel, M. Danhof, C.A. Knibbe: Pilot study on the influence of liver blood flow and cardiac output on the clearance of propofol in critically ill patients.
Eur J Clin Pharmacol. 64(3):329-334(2007)
- 191 P.G. Ravenstijn, M. Merlini, M. Hameetman, T.K. Murray, M.A. Ward, H. Lewis, G. Ball, C. Mottart, C. de Ville de Goyet, T. Lemarchand, K. van Belle, M.J. O'Neill, M. Danhof, E.C. de Lange. The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments.
J Pharmacol Toxicol Methods. 57 (2):114-130 (2007)
- 192 M. Geldof, J.I. Freijer, L. van Beijsterveldt, P.C. Vermote, A.A. Megens, M. Danhof. Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior.
Eur J Pharm Sci.;32(3):200-208 (2007)
- 193 K.P. Zuideveld, P.H. van der Graaf, L.A. Peletier, M. Danhof: Allometric scaling of pharmacodynamic responses: application to 5-HT_{1A} receptor mediated responses from rat to man.
Pharm Res.;24(11):2031-2039 (2007)
- 194 A.E. Muller, J. DeJongh, Y. Bult, W.H. Goessens, J.W. Mouton, M. Danhof, J.N. van den Anker. Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks.
Antimicrob Agents Chemother. 51(10):3720-5. (2007)
- 195 V.V. Anisimov, H.J. Maas, M. Danhof, O. Della Pasqua: Analysis of responses in migraine modelling using hidden Markov models.
Stat Med. 26(22):4163-4178. (2007)
- 196 M. Geldof, J.I. Freijer, L. van Beijsterveldt, M. Danhof. Pharmacokinetic Modeling of Non-Linear Brain Distribution of Fluvoxamine in the Rat.
Pharm Res. 25 (4): 792-804(2007)
- 197 M.Y. Peeters, L.J. Bras, J. DeJongh, R.M. Wesselink, L.P. Aarts, M. Danhof, C.A. Knibbe. Disease Severity Is a Major Determinant for the Pharmacodynamics of Propofol in Critically Ill Patients.
Clin Pharmacol Ther. 83(3): 443-451 (2007)
- 198 D. Groenendaal, J.I. Freijer, D. de Mik, M.R. Bouw, M. Danhof, E.C. de Lange. Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux.
Br J Pharmacol. 151(5):701-712. (2007)
- 199 D. Groenendaal, J.I. Freijer, D. de Mik, M.R. Bouw, M. Danhof, E.C. de Lange. Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-

- pharmacodynamic modelling of the effects of morphine on the EEG.
Br J Pharmacol.;151(5):713-720. (2007)
- 200 L.C. Liefwaard, R.A. Gunput, M. Danhof, R.A. Voskuyl. Decreased Efficacy of GABAA-receptor modulation by midazolam in the kainate model of temporal lobe epilepsy.
Epilepsia: 48(7):1378-1387. (2007)
- 201 T.J. van Steeg, E.H. Krekels, M. Danhof, E.C. de Lange. Reproducible and time-dependent modification of serum protein binding in Wistar Kyoto rats.
J Pharmacol Toxicol Methods: 56(1):72-78 (2007)
- 202 T.J. van Steeg, J.I. Freijer, M. Danhof, E.C. de Lange: Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint.
Br J Pharmacol.;151(3):356-366. (2007)
- 203 A. Yassen, J. Kan, E. Olofsen, E. Suidgeest, A. Dahan, M. Danhof: Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats.
J Pharmacol Exp Ther.;321(2):598-607 (2007)
- 204 D.M. Jonker, R.A. Voskuyl, M. Danhof. Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments?
Epilepsia. 48(3):412-434. (2007).
- 205 P. Rolan, M. Danhof, D. Stanski, C. Peck. Current issues relating to drug safety especially with regard to the use of biomarkers: a meeting report and progress update.
Eur J Pharm Sci.;30(2):107-112. (2007)
- 206 M. Danhof, J. DeJongh, E.C. de Lange, O.E. Della Pasqua, B.A. Ploeger, R.A. Voskuyl. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.
Annu Rev Pharmacol Toxicol.;47:357-400.(2007)
- 207 J.I. Freijer, T.M. Post, B.A. Ploeger, J. DeJongh, M. Danhof: Application of the convection-dispersion equation to modelling oral drug absorption.
Bull Math Biol.;69(1):181-195. (2007)
- 208 A. Yassen, E. Olofsen, E. van Dorp, E. Sarton, L. Teppema, M. Danhof, A. Dahan. Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers.
Clin Pharmacokinet.;46(11):965-980. (2007)
- 209 A. Yassen, E. Olofsen, J. Kan, A. Dahan, M. Danhof. Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine.
Clin Pharmacokinet.;46(5):433-447.(2007)
- 210 A. Yassen, E. Olofsen, R. Romberg, E. Sarton, L. Teppema, M. Danhof, A. Dahan. Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers.
Clin Pharmacol Ther.;81(1):50-58. (2007)
- 211 M. Geldof, J.I. Freijer, L. van Beijsterveldt, P. Timmerman, A. Ahnaou, W.H. Drinkenburg, M. Danhof. Population pharmacokinetic model of fluvoxamine in rats: utility for application in animal behavioral studies.
Eur J Pharm Sci.: 30(1):45-55. 2007
- 212 M.Y. Peeters, S.A. Prins, C.A. Knibbe, J. DeJongh, R.A. Mathôt, C. Warris, R.H. van Schaik, D. Tibboel, M. Danhof. Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery.
Anesthesiology.;105(6):1135-1146. (2006)

- 213 H.J. Maas, M. Danhof, O.E. Della Pasqua. A model-based approach to treatment comparison in acute migraine.
Br J Clin Pharmacol.;62(5):591-600. (2006)
- 214 A. Yassen, J. Kan, E. Olofsen, E. Suidgeest, A. Dahan, M. Danhof. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats.
J Pharmacol Exp Ther.;319(2):682-692. (2006)
- 215 E. van Dorp, A. Yassen, E. Sarton, R. Romberg, E. Olofsen, L. Teppema, M. Danhof, A. Dahan. Naloxone reversal of buprenorphine-induced respiratory depression.
Anesthesiology.;105(1):51-57. (2006)
- 216 A.K. Nugroho, S.G. Romeijn, R. Zwier, J.B. de Vries, D. Dijkstra, H. Wikström, O.E. Della-Pasqua, M. Danhof, J.A. Bouwstra. Pharmacokinetics and pharmacodynamics analysis of transdermal iontophoresis of 5-OH-DPAT in rats: in vitro-in vivo correlation.
J Pharm Sci.;95(7):1570-1585. (2006)
- 217 A. Yassen, E. Olofsen, R. Romberg, E. Sarton, M. Danhof, A. Dahan. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers.
Anesthesiology.;104(6):1232-1242. (2006)
- 218 D.R. Huntjens, D.J. Spalding, M. Danhof, O.E. Della Pasqua. Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers.
Br J Pharmacol.;148(4):396-404. (2006)
- 219 W. de Winter, J. DeJongh, T. Post, B. Ploeger, R. Urquhart, I. Moules, D. Eckland, M. Danhof. A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.
J Pharmacokinetic Pharmacodyn. 33(3):313-343. (2006)
- 220 L.G. Franciosi, C.P. Page, B.R. Celli, M. Cazzola, M.J. Walker, M. Danhof, K.F. Rabe, O.E. Della Pasqua. Markers of exacerbation severity in chronic obstructive pulmonary disease.
Respir Res; 10;7:74. (2006)
- 221 H. Maas, M. Danhof and O.E. della Pasqua: Prediction of headache response in migraine treatment.
Cephalalgia 26: 416-422 (2006).
- 222 W. de Winter, J. DeJongh, T.M. Post, B.A. Ploeger, R. Urquhart, I.A. Moules, D. Eckland and M. Danhof. A Mechanism-based Disease Progression Model for Comparison of Long-term Effects of Pioglitazone, Metformin and Gliclazide on Disease Processes Underlying Type 2 Diabetes Mellitus.
J. Pharmacokin. Pharmacodyn. 33 (3):313-343 (2006)
- 223 A. Dahan, A. Yassen, R. Romberg, E. Sarton, L. Teppema, E. Olofsen and M. Danhof. Buprenorphine induces ceiling in respiratory depression but not in analgesia.
Br. J. Anaesth. 96: 627-632 (2006).
- 224 M.Y.M. Peeters, S.A. Prins, C.A.J. Knibbe, J. DeJongh, R.H. van Schaick, M. van Dijk, I.P. van der Heiden, D. Tibboel and M. Danhof. Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery.
Anesthesiology 104: 466-474 (2006)
- 225 E.L. Swart, K.P. Zuideveld, J. DeJongh, M. Danhof L.G. Thijs, R.M. Strack van Schijndel. Population pharmacodynamic modelling of lorazepam- and midazolam-

- induced sedation upon long-term continuous infusion in critically ill patients.
Eur J Clin Pharmacol. 62:185-194 (2006).
- 226 L.G. Franciosi, C.P. Page, B. R. Celli, M. Cazzola, M. J. Walker, M. Danhof, K. F. Rabe and O.E. Della Pasqua: Markers of disease severity in chronic obstructive pulmonary disease.
Pulmonary Pharmacology & Therapeutics. 19: 189-199 (2006)
- 227 L.C. Liefwaard, B.A. Ploeger, C.F. Molthoff, R. Boellaard, A.A. Lammertsma, M. Danhof and R.A. Voskuyl: Population pharmacokinetic analysis for simultaneous determination of B_{max} and K_D in vivo by positron emission tomography
Mol. Imaging Biol. 7: 411-421 (2005)
- 228 D. Groenendaal, M.C. Blom-Roosemalen, M. Danhof and E.C. De Lange. High performance liquid chromatography of nalbuphine, butorphanol and morphine in blood and brain microdialysate samples: application to pharmacokinetic/ pharmacodynamic studies in rats.
J. Chromatogr. B. 822: 230-237 (2005).
- 229 T.M. Post, J.I. Freijer, J. DeJongh and M. Danhof: Disease System Analysis: basic Disease Progression Models in Degenerative Disease.
Pharm. Res. 22: 1038-1049 (2005)
- 230 G.L. Li, T.J. van Steeg, H. Putter, J. van der Spek, S. Pavel, M. Danhof and J.A. Bouwstra: Cutaneous side-effects of transdermal iontophoresis with and without surfactant pretreatment: a single-blinded, randomized controlled trial.
Br. J. Dermatol. 153: 404-412 (2005).
- 231 C.C. Visser, S. Stevanovic, L.H. Voorwinden, L. van Bloois, P.J. Gaillard, M. Danhof, D.J.A. Crommelin and A.G. de Boer Targeting liposomes with protein drug to the blood-brain barrier in vitro.
Eur J Pharm Sci. 25: 299-305 (2005).
- 232 D.R. Huntjens, M. Danhof and O.E. Della Pasqua: Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors.
Rheumatology (Oxford). 44: 846-859 (2005).
- 233 A.K. Nugroho, O.E. Della-Pasqua, M. Danhof and J.A. Bouwstra. Compartmental modeling of transdermal iontophoretic transport II: in vivo model derivation and application.
Pharm. Res. 22 (3): 335-346 (2005)
- 234 A. Dahan, A. Yassen, H. Bijl, R. Romberg, E. Sarton, L. Teppema, E. Olofsen, and M. Danhof. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats.
Br J Anaesth. 94 (6): 825- 834 (2005)
- 235 S.A. Prins, M.Y. Peeters, R.J. Houmes, M. Van Dijk, C.A. Knibbe, M. Danhof and D. Tibboel. Propofol 6% as sedative in children under 2 years of age following major craniofacial surgery.
Br J Anaesth. 94 (5): 630-635 (2005).
- 236 A.Yassen, E. Olofsen, A. A. Dahan and M. Danhof. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics.
J Pharmacol Exp Ther. 313(3): 1136-1149 (2005)
- 237 M. Danhof, G. Alvan, S.G. Dahl, J. Kuhlmann and G. Paintaud. Mechanism-based Pharmacokinetic-Pharmacodynamic Modelling – A new classification of biomarkers.
Pharm. Res. 22: 1432-1437 (2005).

- 238 M.P. Schaddelee, S.D. Collins, J. DeJongh, A.G. de Boer, A.P. IJzerman, M. Danhof. Pharmacokinetic/Pharmacodynamic modelling of the anti-hyperalgesic and antinociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain. Europ. J. Pharmacol. **514**: 131-140 (2005)
- 239 A.K. Nugroho, G.L. Li, D. Dijkstra, H. Wikstrom, M. Danhof, J.A. Bouwstra. Transdermal iontophoresis of the dopamine agonist 5-OH-DPAT in human skin in vitro. J. Control Release **103**: 393-403 (2005)
- 240 E.L. Swart, J. DeJongh, K.P. Zuideveld, M. Danhof, L.G. Thijs, R.J. Strack van Schijndel. Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. Am J Kidney Dis. **45(2)**:360-371 (2005)
- 241 M.P. Schaddelee, K.D. Read, C.G. Cleypool, A.P. IJzerman, M. Danhof, A.G. de Boer. Brain penetration of synthetic adenosine A(1) receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents. Eur J Pharm Sci. **24(1)**:59-66 (2005).
- 242 D.M. Jonker, S.A.G. Visser, P.H. van der Graaf, R.A. Voskuyl, M. Danhof: Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions *in vivo*. Pharmacol. Ther. **106**: 1-18 (2005).
- 243 C.C. Visser, L.H. Voorwinden, L.R. Harders, M. Eloualid, L. van Bloois, D.J. Crommelin, M. Danhof, A.G. de Boer. Coupling of metal containing homing devices to liposomes via a maleimide linker: use of TCEP to stabilize thiol-groups without scavenging metals. J Drug Target. **12(9-10)**:569-573 (2004).
- 244 M.P. Schaddelee, D. Groenendaal, J. DeJongh, C.G.J. Cleypool, A.P. IJzerman, A.G. de Boer and M. Danhof: Population pharmacokinetic Modeling of Blood-Brain Barrier Transport of Synthetic Adenosine A1 Receptor Agonists. J. Pharmacol. Exp. Ther. **311**: 1138-1146 (2004)
- 245 M.P. Schaddelee, J. DeJongh, S.D. Collins, A.G. de Boer, A.P. IJzerman, M. Danhof: Population pharmacokinetic-pharmacodynamic modelling of the anti-hyperalgesic effect of 5'-deoxy-N⁶-cylopentyladenosine in the mononeuropathic rat. Europ. J. Pharmacol. **504**:7-15 (2004)
- 246 G.L. Li, J.J. de Vries, T.J. van der Steeg, H. van den Bussche, H.J. Maas, H.J.E.M. Reeuwijk, M. Danhof, J.A. Bouwstra and T. van Laar: Transdermal iontophoretic delivery of apomorphine with surfactant pretreatment in patients with Parkinson's disease. J. Contr. Rel. **101**: 199-208 (2005).
- 247 C.A.J. Knibbe, K.P. Zuideveld, L.P.H.J. Aarts, P.F.M. Kuks and M. Danhof. Allometric relations between the pharmacokinetics of propofol in rats, children and adults. Br. J. Clin. Pharm. **59**:705-711 (2005)
- 248 A.K. Nugroho, G.L. Li, M. Danhof, J.A. Bouwstra (2004) Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: influence of pH and NaCl concentration. Pharm Res **21(5)**: 844-50 (2004)
- 249 A.K. Nugroho, G. Li, A. Grossklaus, M. Danhof and J.A. Bouwstra. Transdermal iontophoresis of rotigotine: influence of concentration, temperature and current density in human skin in vitro. J. Contr. Drug Rel. **96**: 159-167 (2004)

- 250 C.C. Visser, S. Stevanovic, L.H. Voorwinden, P.J. Gaillard, D.J.A. Crommelin, M. Danhof and A.G. de Boer. Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro
J. Drug. Target. **12**: 145-150 (2004)
- 251 C.C. Visser, L.H. Voorwinden, D.J.A. Crommelin, M. Danhof and A.G. De Boer. Characterization and Modulation of the Transferrin Receptor on Brain Capillary Endothelial Cells.
Pharm. Res. **21**: 761-769 (2004)
- 252 M. Jonker, R.A. Voskuyl and M. Danhof. Pharmacodynamic analysis of the anticonvulsant effects of tiagabine and lamotrigine in combination in the rat.
Epilepsia. **45**: 424-435 (2004)
- 253 E.L. Swart, K.P. Zuideveld, J. DeJongh, M. Danhof and L.G. Thijs. Population pharmacokinetics of lorazepam and midazolam in ICU patients after long-term continuous infusion.
Br. J. Clin. Pharmacol. **57**:135-145 (2004)
- 254 E.L. Swart, K.P. Zuideveld, J. DeJongh, M. Danhof, L.G. Thijs, R.M. Strack van Schijndel.
Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients.
Br. J. Clin. Pharmacol. **57**:135-45 (2004)
- 255 K.P. Zuideveld, P.H. van der Graaf, D. Newgreen, R. Thurlow, N. Petty, P. Jordan, L.A. Peletier and M. Danhof. Mechanism-based pharmacokinetic/pharmacodynamic modeling of 5-HT_{1A} receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in rats.
J. Pharmacol Exp Ther. **308**: 1012-1020 (2004)
- 256 C.A.J. Knibbe, H. Naber, L.P.H.J. Aarts, P.F.M. Kuks and M. Danhof. Long-term sedation with Propofol 60 mg/ml versus Propofol 10 mg/ml in critically ill, mechanically ventilated patients.
Acta Anaesthesiol. Scand. **48**: 302-307 (2004)
- 257 G. Li, A. Grossklaus, M. Danhof, J.A. Bouwstra. Iontophoretic R-apomorphine delivery in combination with surfactant pretreatment: in vitro validation studies.
Int. J. Pharmac. **266**: 61-68 (2003)
- 258 S.A.G. Visser, D.R.H. Huntjens, P.H. van der Graaf, L.A. Peletier and M. Danhof. Mechanism-Based modeling of the pharmacodynamic interaction of Alphaxalone and midazolam in rats.
J. Pharmacol Exp Ther **307** 365-375 (2003)
- 259 S.A.G. Visser, F.L. Wolters, J.M. Gubbens-Stibbe, E. Tukker, P.H. van der Graaf, L.A. Peletier and M. Danhof. Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABA_A receptor modulators: in vitro-in vivo correlations.
J Pharmacol Exp Ther **304**: (1) 88-101 (2003)
- 260 S.A.G. Visser, F.L. Wolters, P.H. van der Graaf, L.A. Peletier and M. Danhof. Dose-dependent EEG effects of zolpidem provide evidence for GABA(A) receptor subtype selectivity in vivo.
J Pharmacol Exp Ther **304**: (3) 1251-1257 (2003)
- 261 M.P. Schaddelee, H.L. Voorwinden, D. Groenendaal, A. Hersey, A.P. IJzerman, M. Danhof and A.G. de Boer. Blood-brain barrier transport of synthetic adenosine A₁ receptor agonist in vitro: structure transport relationships.
Eur. J. Pharm. Sci. **20**: 347-356 (2003)

- 262 M.P. Schaddelee, H.L. Voorwinden, E.W. van Tilburg, T.J. Pateman, A.P. IJzerman, M. Danhof and A.G. de Boer. Functional role of adenosine receptor subtypes in the regulation of blood-brain barrier permeability: possible implications for the design of synthetic adenosine derivatives.
Eur J Pharm Sci **19**: (1) 13-22 (2003)
- 263 D.M. Jonker, D.A. Vermeij, P.M. Edelbroek, R.A. Voskuyl, V.K. Piotrovsky and M. Danhof. Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction.
Epilepsia **44**: (3) 329-338. (2003)
- 264 D.M. Jonker, C. van de Mheen, P.H.C. Eilers, M.R. Kruk, R.A. Voskuyl and M. Danhof. Anticonvulsant drugs differentially suppress individual ictal signs: a pharmacokinetic/pharmacodynamic analysis in the cortical stimulation model in the rat.
Behavioral-Neuroscience **117**: (5) 1076-1085. (2003)
- 265 T.J.H. Bueters, A.P. IJzerman, H.P. van Helden and M. Danhof. Characterization of the pharmacokinetics, brain distribution, and therapeutic efficacy of the adenosine A1 receptor partial agonist 2'-deoxy-N6-cyclopentyladenosine in sarin-poisoned rats.
Toxicol Appl Pharmacol. **192**: 86-94 (2003)
- 266 T.J.H. Bueters, L.M. van Duivenvoorde, M. Danhof, A.P. IJzerman and H.P.M. van Helden. Cyclopentyladenosine and some of its low-efficacy derivatives inhibit striatal synaptosomal release of acetylcholine to a similar degree.
Eur. J. Pharmacol. **481**: 141-146 (2003)
- 267 T.J.H. Bueters, M.J. Joosen, H.P. van Helden, A.P. IJzerman and M. Danhof. Adenosine A1 receptor agonist N6-cyclopentyladenosine affects the inactivation of acetylcholine-sterase in blood and brain by sarin.
J Pharmacol Exp Ther **304**: (3) 1307-1313. (2003)
- 268 T.J. Bueters, H.P. van Helden, A.P. IJzerman and M. Danhof. Low efficacy adenosine A(1) agonists inhibit striatal acetylcholine release in rats improving central selectivity of action.
Neurosci Lett **343**: (1) 57-61 (2003)
- 269 G.L. Li, M. Danhof, P.M. Frederik and J.A. Bouwstra. Pretreatment with a water-based surfactant formulation affects transdermal iontophoretic delivery of R-apomorphine in vitro.
Pharm Res **20**: (4) 653-659. (2003)
- 270 K.P. Zuideveld, J. Rusic-Pavletic, H.J. Maas, L.A. Peletier, P.H. van der Graaf and M. Danhof. Pharmacokinetic-Pharmacodynamic modeling of buspirone and its metabolite 1-(2-Pyrimidinyl)-Piperazine in rats.
J. Pharmacol. & Exp. Ther. **303** : N3: 1130-1137 (2002).
- 271 M. Danhof. Electroencephalography parameters as biomarkers: extrapolation from laboratory animals to humans.
Methods Find Exp Clin Pharmacol **24**: 63-64 (2002)
- 272 M. Danhof and S.A.G. Visser. Pharmacoelectroencephalography and pharmacokinetic-pharmacodynamic modeling in drug development: focus on preclinical steps.
Methods Find Exp Clin Pharmacol **24**: 127-128 (2002)
- 273 G.L. Li, R. van der Geest, L. Chanet, E. van Zanten, M. Danhof and J.A. Bouwstra. In vitro iontophoresis of R-apomorphine across human stratum corneum. Structure-transport relationship of penetration enhancement.
J Controlled Rel. **84**: 49-57 (2002)

- 274 C.A.J. Knibbe, G. Melenhorst-de Jong, M. Mestrom, C.M.A. Rademaker, A.F.A. Reijnvaan, K.P. Zuideveld, P.F.M. Kuks, H. van Vught and M. Danhof. Pharmacokinetic and effects of propofol 6% for short-term sedation in paediatric patients following cardiac Surgery. Br J Clin Pharmacol. 54: 415-422 (2002).
- 275 T.J.H. Bueters, H.P.M. van Helden, M. Danhof and A.P. IJzerman. Effects of adenosine A1 receptor allosteric modulators PD 81,723 and LUF 5484 on the striatal acetylcholine release. Eur. J. Pharmacol. 454: 177-182 (2002).
- 276 T.J.H. Bueters, B. Groen, M. Danhof, A.P. IJzerman and H.P. van Helden. Therapeutic efficacy of the A1 receptor agonist cyclopentyladenosine (CPA) against organophosphate intoxications. Arch Toxicol. 11: 650-656 (2002)
- 277 S.A.G. Visser, W.W.F.T. Gladdines, P.H. van der Graaf, L.A. Peletier and M. Danhof. Neuroactive Steroids Differ in Potency but Not in Intrinsic Efficacy at the GABAA Receptor in Vivo. J. Pharmacol. Exp. Ther. 303: 616-626 (2002)
- 278 S.A.G. Visser, J.G.M. Smulders, B.P.R. Reijers, PH. Van der Graaf, L.A. Peletier and M. Danhof. Mechanism-based Pharmacokinetic-Pharmacodynamic Modelling of Concentration-Dependent Hysteresis and Biphasic Electroencephalogram Effects of Alphaxalone in Rats. J. Pharmacol & Exp. Ther. 302: 1158-1167 (2002).
- 279 K.P. Zuideveld, A. van Gestel, L.A. Peletier, P.H. van der Graaf and M. Danhof. Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A-receptor agonist flesinoxan. Eur. J. Pharmacol. 445: 43-54 (2002).
- 280 K.P. Zuideveld, N. Treijtel, H.J. Maas, J.M. Gubbens-Stibbe, L.A. Peletier, P.H. van der Graaf and M. Danhof. A competitive interaction model predicts the effect of WAY-100,635 on the Time Course of R-(+)-8-Hydroxy-2-(di-n-propylamino)tetralin-Induced Hypothermia. J. Pharm & Exp. Ther. 300: 330-338 (2002).
- 281 B. Tuk, T. van Gool and M. Danhof. Mechanism-based pharmacodynamic modelling of the interaction of midazolam, bretazenil and zolpidem with ethanol. J. Pharmacok. & Pharmacod. 29: 235-250 (2002)
- 282 C.A.J. Knibbe, K.P. Zuideveld, J. DeJongh, P.F. Kuks, L.P. Aarts and M. Danhof. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. Clin Pharmacol Ther 72: (6) 670-84 (2002)
- 283 E.L. Swart, B. van der Hoven, A.B.J. Groeneveld, D.J. Touw and M. Danhof . Correlation between midazolam and lidocaine pharmacokinetics and MEGX formulation in healthy volunteers. Br. J. Clin. Pharmacol. 53: 133-139 (2002)
- 284 E.C.M. de Lange and M. Danhof. Considerations in the Use of Cerebrospinal Fluid Pharmacokinetics to Predict Brain Target Concentrations in the Clinical Setting; Implications of the Barriers between Blood and Brain. Clin Pharmacokin. V41: 691-703 (2002)
- 285 K.P. Zuideveld, H.J. Maas, N. Treijtel, J. Hulshof, P.H. van der Graaf, L.A. Peletier and M. Danhof. A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia.

- Am J Physiol Reg Integr Comp Physiol **281**: R2059-R2071 (2001).
- 286 G.L. Li, M. Danhof and J.A. Bouwstra. Effect of Elastic Liquid-state vesicle on apomorphine iontophoresis transport through human skin In vitro. Pharm Res. **18**: 1627-1630 (2001).
- 287 G. L. Li, M. Danhof and J.A. Bouwstra. Iontophoretic delivery of Apomorphine in Vitro: Physicochemical considerations. Pharm. Res. **18**: 1509-1513 (2001).
- 288 T.J. Parker, O.E. Della Pasqua, E. Loizillon, C. Chezaubernard, R. Jochemsen, M. Danhof. Pharmacokinetic-Pharmacodynamic modelling in the early development phase of anti-psychotics: a comparison of the effects of clozapine, S 16924 and S 18327 in the EEG model in rats. Br. J. Pharmacol. **132**: 151-158 (2001).
- 289 P. Vis, O. E. Della Pasqua, M. Kruk, Delphine Martin, E. Mocaër, M. Danhof and R. Jochemsen. Population pharmacokinetic-pharmacodynamic modelling of S15535, a 5-HT_{1A} receptor agonist, using a behavioural model in rats. Eur. J. Pharmacol. **414**, 233-243 (2001).
- 290 S. R. Santos, O. Papini, C. E. Omosako, M. D. Pereira, T. B. Quintavalle, M. F. Riccio, A. Kurata, V. A. Pereira, G. Di-Pietro, O. E. Della-Paschoa, M. Danhof and P. L. Da-Luz. A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. Braz J Med Biol Res **33**: (2) 199-204. (2000)
- 291 D.A. Eckland, M. Danhof. Clinical Pharmacokinetics of pioglitazone. Exp.Clin Endocrin. & Diab. **108**: S234-S242 (2000)
- 292 S.A.G. Visser, C.J.G.M. Smulders, W.W.F.T Gladdines, H. Irth, P.H. van der Graaf and M. Danhof. High Performance Liquid Chromatography of the Neuractive Steroids Alphaxalone and Pregnanolone in Plasma using Dansyl Hydrazine as Fluorescent Label: Application to a Pharmacokinetic Study in Rats. J. Chromatogr. **745**: 357-363 (2000).
- 293 C.A.J. Knibbe, L.P.H.J. Aarts, P.F.M. Kuks, H.-J. Voortman, L. Lie-A-Huen, L.J. Bras, M. Danhof. Pharmacokinetics and pharmacodynamics of propofol 6% SAZN versus propofol 1% SAZN and Diprivan-10 for short-term sedation following coronary artery bypass surgery. Eur. J. Clin. Pharmacol. **56**:89-95 (2000)
- 294 M. Garrido, J. Gubbens-Stibbe, E. Tukker, E.H. Cox, J. von Freitag Drabbe Künzel, A.P. IJzerman, M. Danhof and P.H. van der Graaf. Pharmacokinetic-pharmacodynamic analysis of the EEG effect of alfentanil in rats following beta-funaltrexamine-induced mu-opioid receptor “knockdown” in vivo. Pharm. Res. **17**: (6) 653-659 (2000)
- 295 M.O. Karlsson, R.C. Schoemaker, B. Kemp, A.F. Cohen, J. van Gerven, B. Tuk, M. Danhof. A pharmacodynamic Markov mixed effect model for temazepam’s effect on sleep. Clinical Pharmacol. & Ther., **68**: 175-188 (2000)
- 296 K.P. Zuideveld, N. Treijtel, P.H. van der Graaf, M. Danhof. Enantioselective high-performance liquid chromatographic analysis of the 5-HT₁ receptor agonist-8-hydroxy-2-(di-n-propylamino)tetralin: application to a pharmacokinetic-pharmacodynamic study in rats. J. Chromatography B. **738**: 67-73 (2000)
- 297 O.E. Della Paschoa, A. Hoogerkamp, P. Edelbroek, R.A. Voskuyl, M. Danhof. Pharmacokinetic-pharmacodynamic correlation of lamotrigine, flunarizine, loreclezole, CGP40116, and CGP39551 in the cortical stimulation model.

- Epilepsy Res. **40**: 41-52 (2000)
- 298 A. Cleton, B.A. Altorf, R.A. Voskuyl, M. Danhof. Pharmacokinetic-pharmacodynamic modelling of tiagabine CNS effects upon chronic treatment in rats: lack of change in concentration-EEG effect relationship. Eur.J. Pharm. Sci. **12** 141-150 (2000)
- 299 A. Cleton, J. Ödman, P.H. van der Graaf, R.A. Voskuyl, M. Danhof. Mechanism-based modelling of the functional adaptation upon chronic treatment with midazolam. Pharm Res. **17**: (3) 321-327 (2000)
- 300 A. Cleton, B.A. Altorf, R.A. Voskuyl, M. Danhof. Effect of amygdala kindling on the central nervous system effects of tiagabine: EEG effects versus brain GABA levels. Br. J. Pharmacol. **130**: 1037-1044 (2000)
- 301 A. Cleton, P.H. van der Graaf, W. Ghijsen, R. Voskuyl, M. Danhof. Mechanism-based modeling of adaptive changes in the pharmacodynamics of midazolam in the kindling model of epilepsy. Pharm. Res. **16**: 1702-1709 (1999)
- 302 A. Cleton, D. Mazee, R.A. Voskuyl, M. Danhof. Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats. Br. J. Pharmacol. **127**: 227-235 (1999)
- 303 A. Cleton, H.J.M.M. de Greef, P.M. Edelbroek, R.A. Voskuyl and M. Danhof: Stereoselective central nervous system effects of the R- and S-isomers of the GABA uptake blocker N-(4,4-di-(3-methylthien-2-yl)but-3-enyl)nipecotic acid in the rat. Br. J. Pharmacol., **128**: 1651-1658 (1999)
- 304 A. Cleton, H.J.M.M. de Greef, P.M. Edelbroek, R.A. Voskuyl and M. Danhof: Application of a combined "Effect compartment/indirect response model": to the central nervous system effect of tiagabine in the rat. J. Pharmacokin. Biopharm., **27**: 301-323 (1999)
- 305 E. Snoeck, P. Jacqmin, A. van Peer, M. Danhof. A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine. J. Pharmacokin. Biopharm. **27**: 257-281 (1999)
- 306 P.H. van der Graaf, E.A. van Schaick, S.A.G. Visser, H.J.M.M. de Greef, A.P. IJzerman, and M. Danhof: Mechanism-based pharmacokinetic-pharmacodynamic modelling of the anti-lipolytic effects of adenosine A1 receptor agonists in rats: prediction of tissue dependent efficacy in vivo. J. Pharmacol. Exp. Ther., **290**: 702-709 (1999)
- 307 B.Tuk, M.F. van Oostenbruggen, V.M.M. Herben, J.W. Mandema and M. Danhof: Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. J. Pharmacol. Exp. Ther., **289**: 1067-1074 (1999)
- 308 C.A.J. Knibbe, V.S. Koster, L.P.H.J. Aarts, H.J.M. Langemeijer and M. Danhof. Pilot study in humans on the pharmacokinetics and safety of propofol 6% SAZN. Pharm World Sci., **21**: 239-240 (1999)
- 309 C.A.J. Knibbe, H.J. Voortman, L.P.H.J. Aarts, P.F.M. Kuks, R. Lange, H.J.M. Langemeijer and M. Danhof: Pharmacokinetics, induction of anaesthesia and safety characteristics of Propofol 6% SAZN, versus Propofol 1% SAZN and Diprivan-10R after bolus injection. Br. J. Clin. Pharmacol., **47**: 653-660 (1999)
- 310 P.H. van der Graaf, J. Nilsson, E.A. van Schaick and M. Danhof: Multivariate quantitative structure-pharmacokinetic (QSPKR) analysis of adenosine A1 receptor agonists in rat J.Pharm. Sci., **88**: 306-312 (1999)

- 311 E.H. Cox, M.W.E. Langemeijer, J.M. Gubbens-stibbe, K.T. Muir, and M. Danhof. The comparative pharmacodynamics of remifentanyl and its metabolite, GR90291, in a rat EEG model.
Anesthesiology, 90: 535-544 (1999)
- 312 H. E. Boddé, T. Van Laar, R. van der Geest and M. Danhof. An integrated pharmacokinetic-pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson's disease.
Adv Drug Deliv Rev 33: (3) 253-263. (1998)
- 313 O.E. Della Paschoa, M.R. Kruk, R.A. Voskuyl and M. Danhof. Effects of repeated seizure induction on seizure activity and interictal behavior.
Brain Research, 814: 199-208 (1998).
- 314 O.E. Della Paschoa, R.A. Voskuyl and Danhof. Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate.
Br.J. Pharmacol., 125: 1610-1616 (1998)
- 315 O.E. Della Paschoa, M.R. Kruk, R. Hamstra, R.A. Voskuyl and M. Danhof: Pharmacodynamic interaction between phenytoin and sodium valproate changes seizure thresholds and pattern
Br. J. Pharmacol., 125: 997-1004 (1998)
- 316 O.E. Della Paschoa, M.R. Kruk, and M. Danhof. Pharmacokinetic-Pharmacodynamic modelling of behavioral responses
Neuroscience & Biobehavior. 23: 229-236 (1998)
- 317 A. Cleton, R.A. Voskuyl and M. Danhof. Adaptive changes in the pharmacodynamics of midazolam in different experimental models of epilepsy: kindling, cortical stimulation and genetic absence epilepsy.
Br. J. Pharmacol., 125: 615-620 (1998).
- 318 E. Snoeck, K. Ver Donck, P. Jacqmin, H. van Belle, A.G. Dupont, A. van Peer and M. Danhof. Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine.
J. Pharmacol & Exp. Ther., 286: 142-149 (1998).
- 319 B.Tuk, V.M.M. Herben, J.W. Mandema and M. Danhof. Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam.
J. Pharmacol. Exp. Ther., 284: 202-207 (1998).
- 320 E.A. van Schaick, K.P. Zuideveld, H.E. Tukker, M.W.E. Langemeijer, A.P. IJzerman and M. Danhof. Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)-adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action.
J. Pharmacol. Exp. Ther., 287: 21-29 (1998)
- 321 E.A. van Schaick, H.E. Tukker, H.C.P.F. Roelen, A.P. IJzerman and M. Danhof. Selectivity of action of 8-alkylamino analogues of N6-cyclopentyl adenosine in vivo: haemodynamic versus antilipolytic responses in rats.
Br. J. Pharmacol., 124: 607-618 (1998).
- 322 E.A. van Schaick, H.J.M.M. de Greef, A.P. IJzerman and M. Danhof. Physiological Indirect Effect Modelling of the anti-lipolytic effects of adenosine A1 receptor agonists.
J. Pharmacokin. Biopharm. 25: 673-694 (1998)
- 323 E.H. Cox, C.A.J. Knibbe, V.S. Koster, M.W.E. Langemeijer, H.E. Tukker, R. Lange, P.F.M. Kuks, H.J.M. Langemeijer, L.Lie-A-Huen and M. Danhof. Influence of

- different fat emulsion based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol.
Pharm. Res. 15: 442-448 (1998)
- 324 E.H. Cox, T. Kerbusch, P.H. van der Graaf and M. Danhof. Pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of synthetic opioids in the rat. Correlation with binding at the μ -opioid receptor.
J. Pharmacol. Exp. Ther., 284: 1095-1103 (1998).
- 325 E.H. Cox, M.W.E. Langemeijer and M. Danhof. Pharmacokinetic-pharmacodynamic modelling of the analgesic effect of alfentanil in the rat using tooth pulp evoked potentials.
J. Pharmacol. Toxicol. Meth. 39: 19-27 (1998).
- 326 T. van Laar, R. van der Geest, M. Danhof, H.E. Boddé, P.H. Goossens and R.A.C. Roos. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease.
Clin. Neuropharmacol. 21: 159-168 (1998).
- 327 R. van der Geest, T. van Laar, P.P. Kruger, J.M. Gubbens-Stibbe, H.E. Boddé, R.A.C. Roos and M. Danhof. Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease.
Clin. Neuropharmacol. 21: 152-158 (1998)
- 328 R. van der Geest, M. Danhof and H.E. Boddé. Validation and testing of a new iontophoretic continuous flowthrough transport cell.
J. Control. Rel. 51: 85-91 (1998)
- 329 O.E. Della Paschoa, J.W. Mandema, R.A. Voskuyl and M. Danhof. Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant and electroencephalogram effects of phenytoin in rats.
J. Pharmacol. Exp Ther., 284: 460-466 (1998).
- 330 M. Danhof, R. van der Geest, T. van Laar and H.E. Boddé. An integrated pharmacokinetic-pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson's disease.
Adv. Drug Delivery Rev. 33: 253-263 (1998)
- 331 R. van der Geest, T. van Laar, J.M. Gubbens-Stibbe, H.E. Boddé and M. Danhof. Iontophoretic delivery of apomorphine II. An in vivo study in patients with Parkinson's disease.
Pharm. Res., 14: 1803-1809 (1997).
- 332 R. van der Geest, M. Danhof and H.E. Boddé. Iontophoretic delivery of apomorphine I. In vitro optimization and validation.
Pharm. Res., 14: 1797-1802 (1997).
- 333 E.H. Cox, J.G.M. van Hemert, H.J. Tukker and M. Danhof. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats.
J. Pharmacol. Toxicol. Meth., 38: 99-108 (1997).
- 334 C.J.J.G. Bol, M. Danhof, D.R. Stanski and J.W. Mandema. Pharmacokinetic-pharmacodynamic characterization of the cardiovascular, EEG and ventilatory responses of intravenous dexmedetomidine in the rat.
J. Pharmacol. Exp. Ther. 283: 1051-1058 (1997).
- 335 C.J.J.G. Bol, A.P. IJzerman, M. Danhof and J.W. Mandema. Determination of Dexmedetomidine in rat plasma by a sensitive [^3H]cloridine radioreceptor assay.
J. Pharm. Sci., 86: 822-826 (1997).
- 336 E.A. van Schaick, C. Kulkarni, J.K. von Frijtag Drabbe Kunzel, R.A.A. Mathôt, G. Cristalli, A.P. IJzerman and M. Danhof. Time course of action of three adenosine A1

- receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects.
Naunyn Schmiedeberg's Arch. Pharmacol. **356**: 827-837 (1997).
- 337 B.Tuk, J.L. Obery, M.S.M. Pieters, R.C. Schoemaker, B. Kemp, J. van Gerven, M. Danhof, H.A.C. Kamphuisen, A.F. Cohen, D.D. Breimer and C.C. Peck. Pharmacodynamics of temazepam in primary insomnia: Assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement of sleep.
Clin Pharmacol Ther. **62**: 444-452 (1997).
- 338 P.H. van der Graaf and M. Danhof. On the reliability of affinity and efficacy estimates obtained by direct operational model fitting of agonist concentration-effect curves following irreversible receptor inactivation.
J Pharmacol & Toxicol Meth. **38**: 81-85 (1997).
- 339 E.A. van Schaick, R.A.A. Mathôt, J.M. Gubbens-stibbe, M.W.E. Langemeijer, H.C.P.F. Roelen, A.P. IJzerman and M. Danhof. 8-Alkylamino-substituted analogues of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo.
J Pharmacol & Exp. Ther., **283**: 800-808 (1997)
- 340 R. van der Geest, P.P. Kruger, J.M. Gubbens-Stibbe, T. van Laar, H.E. Boddé, M. Danhof. Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease.
J Chromatography B., **702**: 131-141 (1997)
- 341 E.C.M. de Lange, M. Danhof, A.G. de Boer and D.D Breimer. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier.
Brain Res Rev., **25**: 27-49 (1997)
- 342 O.E. Della Paschoa, M.R. Kruk, R. Hamstra, R.A. Voskuyl, and M. Danhof. Seizure patterns in kindling and cortical stimulation models of experimental epilepsy.
Brain Res., **770**: 221-227 (1997)
- 343 P.H. van der Graaf, E.A. van Schaick, R.A.A. Mathôt, A.P. IJzerman and M. Danhof. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-Cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors.
J. Pharmacol. Exp. Ther., **283**: 809-816 (1997)
- 344 P.H. van der Graaf and M. Danhof. Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling.
Int. J. Clin. Pharmacol. Ther., **35**: 442-446 (1997)
- 345 D.D. Breimer and M. Danhof: Relevance of the application of PK/PD modelling concepts in drug development: the wooden shoe paradigm
Clin. Pharmacokin., **32**: 259-267 (1997)
- 346 E.A. Van Schaick, H.J.M.M. de Greef, M.W.E. Langemeijer, M.J. Sheehan, A.P. IJzerman and M. Danhof: Pharmacokinetic-pharmacodynamic modelling of the anti-lipolytic and anti-ketotic effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl) adenosine in rats.
Br. J. Pharmacol., **122**: 525-533 (1997).
- 347 B.Tuk, M. Danhof and J.W. Mandema: The impact of arterio-venous concentration differences on pharmacodynamic parameter estimates
J. Pharmacokin. Biopharm., **25**, 39-62 (1997)

- 348 E. Snoeck, V. Piotrovsky, P. Jacqmin, R.L. Lins, A. Van Peer, M. Danhof, R. Woestenborghs, R. van Gool, A.G. Dupont, J. Heykants: Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations.
Eur. J. Clin. Pharmacol., 53: 57-63 (1997).
- 349 E. Snoeck, V. Piotrovsky, P. Jacqmin, A. van Peer, M. Danhof, K. Ver Donck, R. Woestenborghs, H. van Belle, L. van Bortel, R. van Gool, A. Dupont, J. Heykants: Population analysis of the non-linear red blood cell partitioning and the concentration-effect relationship of the nucleoside transport inhibitor draflazine
Br. J. Clin. Pharmacol., 43: 603-612 (1997)
- 350 E. Snoeck, P. Jacqmin, A. van Peer, M. Danhof, K. Ver Donck, H. van Belle, R. Woestenborghs, R. Crabbe, R. van Gool, A Dupont, J. Heykants: The implications of nonlinear red blood cell partitioning in the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine
Br. J. Clin. Pharmacol. 42: 605-613 (1996)
- 351 R.A.A. Mathôt, E.M. van der Wenden, W. Soudijn, D.D. Breimer, A.P. IJzerman, M. Danhof: Partial agonism of the non-selective adenosine receptor agonist 8-nutylaminoadenosine at the A1 receptor in vivo
J. Pharmacol. Exp. Ther., 279: 1439-1446 (1996)
- 352 P.W. Hoogerkamp, R.H.G.P. Arends, A.M. Bomers, J.W. Mandema, R.A. Voskuyl, M. Danhof: Pharmacokinetic-pharmacodynamic relationship of benzodiazepines in the direct cortical stimulation model of anticonvulsant effect
J. Pharmacol. Exp. Ther., 279: 803-812 (1996)
- 353 A.A. Vinks, J.W. Mouton, D.J. Touw, H.G.M. Heijerman, M. Danhof and W. Bakker: Population pharmacokinetics of ceftazidime in cystic fibrosis patients by using a nonparametric algorithm and optimal sampling strategy.
Antimicrob. Agents Chemother., 40: 1091-1097 (1996)
- 354 E.A. van Schaick, K.A. Jacobson, H.O. Kim, A.P. IJzerman, M. Danhof: Haemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats
Eur. J. Pharmacol., 308: 311-314 (1996)
- 355 R.A.A. Mathôt, W. Soudijn, D.D. Breimer, A.P. IJzerman, M. Danhof: Pharmacokinetic -haemodynamic relationships of 2-chloroadenosine at adenosine A1 and A2a receptors in vivo
Br. J. Pharmacol., 118: 369-377 (1996)
- 356 R. van der Geest, D.A.R. Elshove, M. Danhof, A.P.M. Lavrijssen and H.E. Boddé: Non-invasive assessment of skin barrier integrity and skin irritation following iontophoretic current application in humans.
J. Control. Rel., 43: 205-214 (1996)
- 357 T van Laar, C. Neef, M. Danhof, R.I. Kroon, R.A.C. Roos: A new sublingual formulation of apomorphine in the treatment of Parkinson's disease
Mov. Disord., 11: 633-638, (1996)
- 358 T. van Laar, E.N.H. Jansen, C. Neef, M. Danhof, R.A.C. Roos: Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study with five different suppositories
Mov. Disord., 10: 433-439 (1995)
- 359 E.M. van der Wenden, H.R. Hartig-Witte, H.C.P. Roelen, J.K. von Frijtag Drabbe Künzel, I.M. Pirovano, R.A.A. Mathôt, M. Danhof, A van Aerschot, M.J. Lidaks, A.P. IJzerman, W. Soudijn: 8-Substituted adenosine and theophylline-7-ribose analogues as potential partial agonists for the adenosine A1 receptor.

- Eur. J. Pharmacol., 290: 189-199 (1995)
- 360 E.M. van der Wenden, J.K. von Frijtag Drabbe Künzel, R.A.A. Mathôt, M. Danhof, A.P. IJzerman, W. Soudijn: Ribose modified adenosine analogues as potential partial agonists for the adenosine receptor.
J. Med Chem., 38: 4000-4006 (1995)
- 361 E.C.M. De Lange, J.D. De Vries, M. Danhof, C. Zürcher, A.G. De Boer and D.D. Breimer: The use of intracerebral microdialysis for determination of pharmacokinetic profiles of anticancer drugs in tumor bearing rat brain.
Pharm. Res., 12: 1924-1931 (1995)
- 362 E.C.M. De Lange, M. Danhof, C. Zürcher, A.G. De Boer and D.D. Breimer: Repeated microdialysis perfusions: periprobe tissue reactions and BBB permeability.
Brain Res., 702: 261-265 (1995)
- 363 E.C.M. De Lange, M.R. Bouw, M. Danhof, A.G. De Boer and D.D. Breimer: Application of intracerebral microdialysis to study regional distribution kinetics of drugs in rat brain.
Br. J. Pharmacol., 116: 2538-2544 (1995)
- 364 E.C.M. De Lange, M.B. Hesselink, M. Danhof, A.G. De Boer and D.D. Breimer: The use of intracerebral microdialysis to determine changes in blood-brain barrier transport characteristics.
Pharm. Res., 12: 129-133 (1995)
- 365 R.A.A. Mathôt, E.M. Van der Wenden, W. Soudijn, A.P. IJzerman and M. Danhof: Deoxyribose analogues of N6-cyclopentyladenosine (CPA) are partial agonists at the Adenosine A1 receptor in vivo.
Br. J. Pharmacol., 116: 1957-1964 (1995)
- 366 S. Appel, R.A.A. Mathot, M.W.E. Langemeijer, A.P. IJzerman and M. Danhof: Modelling of the In Vivo Interaction of an A1 Adenosine Receptor Agonist and Antagonist: N6-Cyclopentyladenosine and 8-Cyclopentyltheophylline
Br. J. Pharmacol., 115: 1253-1259 (1995)
- 367 R.A.A. Mathôt, J.M. Gubbens-Stibbe, W. Soudijn, K.A. Jacobson, A.P. IJzerman and M. Danhof: Quantification of the in vivo potency of the Adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine (CSC).
J. Pharmacol. Exp. Ther., 275: 245-253 (1995)
- 368 C. Hoyo-Vadillo, J.W. Mandema and M. Danhof: Synergistic pharmacodynamic interaction between midazolam and low doses of ethanol in vivo.
Life Sci., 57: 325-334 (1995)
- 369 R.A.A. Mathôt, B.C.F.M. van den Aarsen, W. Soudijn, D.D. Breimer, A.P. IJzerman and M. Danhof: Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of R- and S-N6-Phenylisopropyladenosine (PIA) in conscious normotensive rats.
J. Pharmacol. Exp. Ther., 273: 401-414 (1995)
- 370 R.A.A. Mathôt, A. Cleton, W. Soudijn, A.P. IJzerman and M. Danhof: The relationship between the pharmacokinetics and the haemodynamic effects of the selective A2 receptor agonist CGS 21680C in conscious normotensive rats.
Br. J. Pharmacol., 114: 761-768 (1995)
- 371 A.P. IJzerman, E.M. van der Wenden, J.K. von Frijtag Drabbe Künzel, R.A.A. Mathôt, M. Danhof, P.A. Borea and K. Varani: Partial agonism of theophylline-7-ribose on adenosine receptors.
Naunyn Schmiedeberg's Arch. Pharmacol., 350: 109-112 (1994)

- 372 H. Irth, A. Cleton, R.A.A. Mathôt, M. Danhof, U.R. Tjaden and J. van der Greef: Liquid chromatographic determination of CGS 21680 in blood using on-line solid-phase extraction on a phenylboronic acid support and fluorescence detection. J. Chromatogr. Biomed. Appl., **658**: 207-212 (1994)
- 373 A.A. Vinks, D.J. Touw, H.G.M. Heijerman, G. de Leede, M. Danhof and W. Bakker: Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Therap. Drug. Monit., **16**: 341-348 (1994)
- 374 E.C.M. de Lange, M.B. Hesselink, M. Danhof, A.G. de Boer and D.D. Breimer: The use of intracerebral microdialysis to determine changes in blood-brain barrier transport characteristics. Pharm. Res., **12**: 129-133 (1994)
- 375 E.C.M. de Lange, M. Danhof, A.G. de Boer and D.D. Breimer: Critical factors of intracerebral microdialysis as a technique to determine the pharmacokinetics of drugs in rat brain Brain Res., **666**: 1-8 (1994)
- 376 A.G. de Boer, H.E. de Vries, E.C.M. de Lange, M. Danhof, J. Kuiper and D.D. Breimer: Drug Transport to the brain: in vitro versus in vivo approaches. J. Control. Rel., **28**: 259-263 (1994)
- 377 P.W. Hoogerkamp, M. Vis, M. Danhof and R.A. Voskuyl: Characterization of the pharmacodynamics of several anti-epileptic drugs in a direct cortical stimulation model of anticonvulsant effect in the rat. J. Pharmacol. Exp. Ther., **269**: 521-528 (1994)
- 378 R.A.A. Mathôt, B.C.F.M. van den Aarsen, A.P. IJzerman and M. Danhof: Assessment of the enantiomeric purity of the adenosine A1 receptor agonists R and S N6-phenylisopropyladenosine (PIA). Naunyn Schmiedeberg's Arch. Pharmacol., **350**: 109-112 (1994)
- 379 R.A.A. Mathôt, E.A. van Schaick, M.W.E. Langemeijer, D.D. Breimer, W. Soudijn, A.P. IJzerman and M. Danhof: Pharmacokinetic-Pharmacodynamic Relationship of the Cardiovascular Effects of Adenosine A1 Receptor Agonist N6-Cyclopentyladenosine (CPA) in the Rat. J. Pharmacol. Exp. Ther., **268**: 616-624 (1994)
- 380 R.A.A. Mathôt, S. Appel, E.A. van Schaick, W. Soudijn, A.P. IJzerman and M. Danhof: High Performance Liquid Chromatography of the Adenosine A1 Agonist N6-Cyclopentyladenosine and the Antagonist 8-cyclopentyltheophylline and its Application in a Pharmacokinetic Study in Rats. J. Chromatogr. Biomed. Appl., **620**: 113-120 (1993)
- 381 A.L. van Steveninck, J.W. Mandema, B. Tuk, J.G. van Dijk, H.C. Schoemaker, M. Danhof and A.F. Cohen: A comparison of methods used to evaluate concentration-effect relationships of midazolam. Br. J. Clin. Pharmacol., **36**: 109-115 (1993)
- 382 A.M. Stijnen, S. Hovinga, M.W.E. Langemeijer, A. Hoogerkamp, C.F.A. van Bezooijen and M. Danhof: The Pharmacodynamics of Sodium Valproate in Ageing BN/BiRij Rats. Pharm. Res., **10**: 1046-1051 (1993)
- 383 M. Danhof, J.W. Mandema, A. Hoogerkamp and R.A.A. Mathôt: Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives. Europ. J. Drug. Metab. Pharmacokin., **18**: 41-47 (1993)

- 384 J.B.M.M. van Bree, A.G. de Boer, M. Danhof and D.D. Breimer: Drug transport across the blood-brain barrier III. Opportunities for modification of drug transport. Pharmacy World and Science, 15: 2-9 (1993)
- 385 M. Danhof and J.W. Mandema, Modelling of the pharmacodynamics and pharmacodynamic interactions of CNS active drugs. Int. J. Clin. Pharmacol. Ther. Toxicol., 30: 516-519 (1992)
- 386 R.A. Voskuyl, A. Hoogerkamp and M. Danhof: Properties of the Convulsive Threshold Determined by Direct Cortical Stimulation. Epilepsy Res., 12: 111-120 (1992)
- 387 A.M. Stijnen, M. Danhof and C.F.A. van Bezooijen: Age and the Pharmacokinetic-Pharmacodynamic Relationship of Phenobarbital in Rats: 'Pseudo'-longitudinal versus Cross-Sectional Study Design. Pharm. Res., 9: 1456-1459 (1992)
- 388 S. Hovinga, A.M. Stijnen, M.W.E. Langemeijer, J.W. Mandema, C.F.A. van Bezooijen and M. Danhof: Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij Rats. Br. J. Pharmacol., 107: 171-177 (1992)
- 389 A.M. Stijnen, I. Postel-Westra, M.W.E. Langemeijer, A. Hoogerkamp, R.A. Voskuyl, C.F.A. van Bezooijen and M. Danhof: Pharmacodynamics of the anticonvulsant effect of oxazepam in aging BN/BiRij Rats. Br. J. Pharmacol., 107: 165-170 (1992)
- 390 A.M. Stijnen, C.E.M. Heeremans, C.F.A. van Bezooijen, W.M.A. Niessen and M. Danhof: Disposition of heptabarbital in the rat: identification of a new metabolite by tandem mass spectrometry. J. Pharm. Pharmacol., 44: 907-910 (1992)
- 391 A.M. Stijnen, M. Danhof and C.F.A. van Bezooijen: Increased Sensitivity to the Anesthetic Effect of Phenobarbital in Aging BN/BiRij Rats J. Pharmacol. Exp. Ther. 261: 81-87 (1992)
- 392 P.A. Soons, G. van den Berg, M. Danhof, P. van Brummelen, J.B.J.M. Jansen, C.B.H.W. Lamers and D.D. Breimer: Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. Europ. J. Clin. Pharmacol., 42: 319-324 (1992)
- 393 J.B.M.M. van Bree, A.G. de Boer, M. Danhof and D.D. Breimer: Drug transport across the blood-brain barrier II. Experimental techniques to study drug transport. Pharm. Weekbl. Sci. Ed., 14: 338-348 (1992)
- 394 J.B.M.M. van Bree, A.G. de Boer, M. Danhof and D.D. Breimer: Drug transport across the blood-brain barrier I. Anatomical and physiological aspects. Pharm. Weekbl. Sci. Ed., 14: 305-310 (1992)
- 395 J.W. Mandema and M. Danhof: EEG effect measures and relationships between pharmacokinetics and pharmacodynamics of psychotropic drugs. Clin. Pharmacokin., 23: 191-215 (1992)
- 396 J.W. Mandema, B. Tuk, A.L. van Steveninck, D.D. Breimer, A.F. Cohen and M. Danhof: Pharmacokinetic-pharmacodynamic modelling of the CNS effects of midazolam and its main metabolite?-hydroxymidazolam in healthy volunteers. Clin. Pharmacol. Ther., 51: 715-728 (1992)
- 397 J.W. Mandema, M.T. Kuck and M. Danhof: In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic activity. J. Pharmacol. Exp. Ther. 261: 56-61 (1992)

- 398 J.W. Mandema, C.D. Heijligers-Feijen, E. Tukker, A.G. de Boer and M. Danhof: Modelling of the effect site equilibration kinetics and pharmacodynamics of racemic baclofen and its enantiomers using quantitative EEG effect measurements. J. Pharmacol. Exp. Ther. **261**: 88-95 (1992)
- 399 J.W. Mandema, P. Veng-Pedersen and M. Danhof: Estimation of amobarbital plasma effect site equilibration kinetics. Relevance of poly-exponential conductance functions. J. Pharmacokin. Biopharm. **19**: 617-634 (1992)
- 400 J.W. Mandema, E. Tukker and M. Danhof: In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil J. Pharmacol. Exp. Ther. **260**: 36-44 (1992)
- 401 J.W. Mandema, M.T. Kuck and M. Danhof: Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship. Br. J. Pharmacol. **105**: 164-170 (1992)
- 402 M. Danhof, A. de Boer, J.C.J. Stiekema and H.N. Magnani: Pharmacokinetic considerations on Lomoparan (Org 10172) therapy. Haemostasis **22**: 73-84 (1992)
- 403 L. Aarons, J.W. Mandema and M. Danhof: A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat. J. Pharmacokin. Biopharm. **19**: 485-496 (1991)
- 404 J.W. Mandema, L.N. Sansom, M.C. Dios-Vièitez, M. Hollander-Jansen and M. Danhof: Pharmacokinetic-pharmacodynamic modelling of the EEG effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. J. Pharmacol. Exp. Ther. **257**: 472-478 (1991)
- 405 J.W. Mandema, H.J. Tukker and M. Danhof: Pharmacokinetic- Pharmacodynamic Modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration Br. J. Pharmacol. **102**: 663-668 (1991)
- 406 J.W. Mandema, J.M. Gubbens-Stibbe and M. Danhof: Stability and Pharmacokinetics of Flumazenil in the rat. Psychopharmacology **103**: 384-387 (1991)
- 407 P. Veng-Pedersen, J.W. Mandema and M. Danhof: Biophase Equilibration Times. J. Pharm. Sci. **80**: 881-886 (1991)
- 408 P. Veng-Pedersen, J.W. Mandema and M. Danhof: A system approach to pharmacodynamics III. An algorithm and computer program COLAPS for pharmacodynamic modeling J. Pharm. Sci. **80**: 488-495 (1991)
- 409 L.T.M. Breimer, A.G.L. Burm, M. Danhof, P.J. Hennis, A.A. Vletter, J.W.H. de Voogt, J. Spierdijk and J.G. Bovill: Pharmacokinetic-Pharmacodynamic modelling of the Interaction between Flumazenil and Midazolam in Volunteers with Aperiodic EEG analysis Clin. Pharmacokin. **20**: 497-508 (1991)
- 410 L.T.M. Breimer, P.J. Hennis, A.G.L. Burm, M. Danhof, J.G. Bovill, A.A. Vletter and J.W.H. de Voogt: EEG effects and Pharmacokinetics of a high dose of Flumazenil in volunteers Clin. Pharmacokin. **20**: 491-496 (1991)
- 411 C.E.M. Heeremans, A.M. Stijnen, R.A.M. van der Hoeven, W.M.A. Niessen, M. Danhof and J. van der Greef: Thermospray liquid chromatography/tandem mass spectrometry for identification of a heptabarbital metabolite and sample work-up artefacts.

- J. Chromatogr., 554: 205-214 (1991)
- 412 R. Koopmans, J. Dingemanse, M. Danhof, G.P.M. Horsten and C.J. van Boxtel: The influence of dosage time midazolam on its pharmacokinetics and effects in humans. Clin. Pharmacol. Ther., 50: 16-24 (1991).
- 413 A. de Boer, J.C.J. Stiekema, M. Danhof, Th.G. van Dinther, J.K. Boeijinga, A.F. Cohen and D.D. Breimer: Interaction studies of a low molecular weight heparinoid (Org 10172) with cloxacillin and ticarcillin in healthy male volunteers Antimicrob. Agents and Chemotherapy 35: 2110-2115 (1991)
- 414 A. de Boer, J.C.J. Stiekema, M. Danhof and D.D. Breimer: The influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (LomoparanR) a low molecular weight heparinoid, in healthy volunteers J. Clin. Pharmacol. 31: 611-617 (1991)
- 415 A. de Boer, J.C.J. Stiekema, M. Danhof and D.D. Breimer: The influence of Org 10172, a low molecular weight heparinoid, on oxidative drug metabolizing enzyme activity and vice versa in healthy volunteers Br. J. Clin. Pharmacol. 32: 23-29 (1991)
- 416 de Boer, J.C.J. Stiekema, M. Danhof and D.D. Breimer: An interaction study of Org 10172 (LomoparanR) and digoxin in six healthy male volunteers Europ. J. Clin. Pharmacol. 41: 245-250 (1991)
- 417 de Boer, M. Danhof, A.F. Cohen, H.N. Magnani and D.D. Breimer: Interaction study between Org 10172 (LomoparanR) a low molecular weight heparinoid and acetyl salicylic acid in healthy male volunteers. Thrombosis and Haemostasis 66: 202-207 (1991)
- 418 W.F. Ebling, M. Danhof and D.R. Stanski: Pharmacodynamic characterization of the electroencephalographic effects of thiopental in rats J. Pharmacokin. Biopharm. 19: 123-143 (1991)
- 419 J.B.M.M. van Bree, C.D. Heijligers-Feijen, A.G. de Boer and D.D. Breimer: Stereoselective transport of baclofen across the blood-brain barrier in rats as determined by the unit impulse response methodology. Pharm. Res. 8: 259-262 (1991)
- 420 J.C.J. Stiekema, A. de Boer, M. Danhof, C. Kroon, A.W. Broekmans, Th.J. van Dinther, J. Voerman and D.D. Breimer: An interaction study of the new low molecular weight heparinoid LomoparanR and Acenocoumarol in healthy volunteers Haemostasis 20: 136-146 (1990)
- 421 J.W. Mandema and M. Danhof. Pharmacokinetic-pharmacodynamic modelling of CNS effects of heptabarbital in rats using aperiodic EEG analysis. J. Pharmacokin. Biopharm. 18: 459-481 (1990)
- 422 J.B.M.M. van Bree, A.G. de Boer, J.C. Verhoef, M. Danhof and D.D. Breimer: Peptide transport across the blood-brain barrier. J. Control. Rel. 13: 175-184 (1990)
- 423 L.T.M. Breimer, P.J. Hennis, A.G.L. Burm, M. Danhof, J.G. Bovill, J. Spierdijk and A. Vletter: Quantification of the EEG effect of midazolam in volunteers: pharmacokinetic/ pharmacodynamic modelling Clin.Pharmacokin. 18: 245-253 (1990)
- 424 J. Dingemanse, R.A. Voskuyl, M.W.E. Langemeyer, I. Postel-Westra, D.D. Breimer, H. Meinardi and M. Danhof: Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats. Br. J. Pharmacol. 99: 53-58 (1990)

- 425 J. Dingemanse, B.M. Hameter and M. Danhof: Pharmacokinetic modelling of tolerance development to the anesthetic and anticonvulsant effects of Phenobarbital in rats.
J. Pharm. Sci. 79: 207-211 (1990)
- 426 J.B.M.M. van Bree, S. Tio, A.G. de Boer, M. Danhof, J.C. Verhoef and D.D. Breimer: Transport of desglycinamide arginine vasopressin across the blood-barrier in rats as evaluated by the unit impulse response methodology.
Pharm. Res. 7: 292-297 (1990)
- 427 J.B.M.M. van Bree, A.V. Baljet, A. van Geyt, A.G. de Boer, M. Danhof and D.D. Breimer: The unit impulse response procedure for pharmacokinetic evaluation of drug entry into the central nervous system.
J. Pharmacokin. Biopharm. 17: 441-462 (1989)
- 428 J. Verhoeven, S.C. Schutte, L.J.C. Pesschier, M. Danhof and H.E. Junginger: Design of a dry-coated controlled release tablet for oxprenolol with microporous polypropylene powder.
J. Control Rel. 10: 205-217 (1989)
- 429 H.E. Junginger, J. Verhoeven and M. Danhof: Oral controlled drug delivery systems based on microporous polymers.
Drug. Dev. Indust. Pharm. 15: 1059-1072 (1989)
- 430 R.A. Voskuyl, J. Dingemanse and M. Danhof: Consecutive determination of the threshold for convulsion by cortical pulse trains of increasing intensity.
Epilepsy Research. 3: 120-129 (1989)
- 431 J. van Harten, J. Burggraaf, M. Danhof, P. van Brummelen and D.D. Breimer: The contribution of nisoldipine induced changes in liver bloodflow to its pharmacokinetics after oral administration.
Br. J. Clin. Pharmacol. 27: 581-586 (1989)
- 432 J. van Harten, P. van Brummelen, P. Ooms, M. Danhof, G.J. Blauw and D.D. Breimer: Variability in the pharmacokinetics of nisoldipine as caused by differences in liver blood flow response.
J. Clin. Pharmacol. 29: 714-721 (1989)
- 433 J. van Harten, P. van Brummelen, M. Danhof, R.P.Ch. Quekel and D.D. Breimer: Pharmacokinetics and hemodynamic effects of long term nisoldipine treatment in hypertensive patients.
J. Cardiovascul. Pharmacol. 13: 624-629 (1989)
- 434 M. Hollander-Jansen, J. Dingemanse, M.W.E. Langemeijer and M. Danhof: Relationship between receptor occupancy and anti-convulsant effect of flunitrazepam in rats.
Pharm. Res. 6: 585-591 (1989)
- 435 J. Dingemanse, J.B.M.M. van Bree and M. Danhof: Pharmacokinetic modelling of the anti convulsant response of phenobarbital in rats.
J. Pharmacol. Exp. Ther. 249: 601-609 (1989)
- 436 J.B.M.M. van Bree, A.G. de Boer, J. Verhoef, M. Danhof and D.D. Breimer: Transport of Vasopressin Fragments Across the Blood-Brain Barrier: in vitro Studies Using Monolayer Cultures of Bovine Brain Endothelial Cells.
J. Pharmacol. Exp. Ther. 249: 1836-1840 (1989).
- 437 J.B.M.M. van Bree, A.G. de Boer, M. Danhof, L.A. Ginsel and D.D. Breimer: Characterization of the "in vitro" blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs.
J. Pharmacol. Exp. Ther. 247: 1233-1239 (1988)

- 438 J.B.M.M. van Bree, J. Verhoef, A.G. de Boer, M. Danhof, T.B. van Wimersma Greidanus and D.D. Breimer. Radio-immuno assay of DGAVP and its application in a pharmacokinetic study in the rat.
Peptides 9: 555-559 (1988)
- 439 J. Verhoeven, L.J.C. Pesschier, M. Danhof and H. Junginger: A controlled release tablet of furosemide: design, in vitro evaluation, pharmacological and pharmacodynamic evaluation.
Int. J. Pharm. 45: 65-77 (1988)
- 440 J.H.M. Schellens, J.H.F. van der Wart, M. Danhof, E.A. van der Velde and D.D. Breimer: Relationship between the metabolism of antipyrine, hexobarbitone and theophylline as assessed by a 'cocktail' approach.
Br. J. Clin. Pharmacol. 26: 373-384 (1988)
- 441 R.P. Koopmans, J. Dingemans, M. Danhof, G.P.M. Horsten and C.J. van Boxtel: Pharmacokinetic-pharmacodynamic modelling of midazolam effects on the human central nervous system.
Clin. Pharmacol. Ther. 44: 14-22 (1988)
- 442 J. Dingemans, F.A.E. Sollie, D.D. Breimer and M. Danhof: Pharmacokinetic modelling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold as a pharmacodynamic measure.
J. Pharmacokin. Biopharm. 16: 203-228 (1988)
- 443 J. Dingemans, M. Polhuys and M. Danhof: Altered Pharmacokinetic-pharmacodynamic relationship of heptabarbital in experimental renal failure in rats.
J. Pharmacol. Exp. Ther. 241: 371-376 (1988)
- 444 J. Dingemans, D. Thomassen, B.H. Mentink and M. Danhof: Strategy to assess the role of (inter)active metabolites in pharmacodynamic studies in vivo: a model study with heptabarbital.
J. Pharm. Pharmacol 40: 552-557 (1988)
- 445 J. Dingemans, P.H. Hutson, M.W.E. Langemeyer, G. Curzon and M. Danhof: Application of serial sampling of cerebrospinal fluid in pharmacodynamic studies with a drug active in the CNS: heptabarbital concentrations at onset and offset of loss of righting reflex in rats.
Neuropharmacology 5: 467-474 (1988)
- 446 J. Dingemans, M. Danhof and D.D. Breimer: Pharmacokinetic-Pharmacodynamic modelling of CNS drug effect. An overview.
Pharmacol. Ther. 38: 1-52 (1988)
- 447 J. van Harten, P. van Brummelen, R.R.E.C.M. Zeegers, M. Danhof and D.D. Breimer: The influence of infusion rate on the pharmacokinetics and haemodynamic effects of nisoldipine in man.
Br. J. Clin. Pharmacol. 25:709-717 (1988)
- 448 J. van Harten, P. van Brummelen, M.Th.M. Lodewijks, M. Danhof and D.D. Breimer: Pharmacokinetics and hemodynamic effects of nisoldipine and its interactions with cimetidine.
Clin. Pharmacol. Ther. 43:332-341 (1988)
- 449 J. van Harten, J. Burggraaf, M. Danhof, P. van Brummelen and D.D. Breimer: Negligible sublingual absorption of nifedipine
Lancet ii: 1363-1365 (1987)
- 450 J. Posner, M. Danhof, M.W.E. Teunissen, D.D. Breimer and P.D. Whiteman: The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.
Br. J. Clin. Pharmacol. 24:51-55 (1987)

- 451 C.H. Kleinbloesem, P. van Brummelen, M. Danhof, H. Faber, J. Urquhart and D.D. Breimer: Rate of increase in plasma concentration of nifedipine as a major determinant of its haemodynamic effects in humans. Clin. Pharmacol. Ther. 41:26-30 (1987)
- 452 R.M. Lequin, A. Van den Boogaard, J. Vermeulen and M. Danhof: Progesterone in saliva: Pitfalls and consequent implications for the accuracy of the determination. Clin. Chem. 32:831-834 (1986)
- 453 C.H. Kleinbloesem, J. van Harten, J.P.H. Wilson, P. van Brummelen, M. Danhof and D.D. Breimer. Nifedipine: Kinetics and haemodynamic effects in patients with liver cirrhosis after i.v. and oral administration. Clin. Pharmacol. Ther. 21:21-28 (1986)
- 454 C.H. Kleinbloesem, P. van Brummelen, J. van Harten, M. Danhof and D.D. Breimer: Pharmacokinetics and haemodynamic effects of nifedipine in patients with different degrees of impaired renal function. Clin. Pharmacol. Ther. 37:563-574 (1985)
- 455 M. Danhof, M. Hisaoka and G. Levy: Kinetics of drug action in disease states. XII. Effect of experimental liver disease on the pharmacodynamics of phenobarbital and ethanol in rats. J. Pharm. Sci. 74: 321-324 (1985)
- 456 M. Hisaoka, M. Danhof and G. Levy: Kinetics of drug action in disease states. VII. Effect of experimental renal dysfunction on the pharmacodynamics of ethanol in rats. J. Pharmacol. Exp. Ther. 232:717-721 (1985)
- 457 M. Danhof, M. Hisaoka and G. Levy: Kinetics of drug action in disease states. VI. Effect of experimental diabetes on phenobarbital concentrations in rats at onset of loss of righting reflex. J. Pharmacol. Exp. Ther. 232:435-439 (1985)
- 458 M. Danhof and G. Levy: Kinetics of drug action in disease states. V. Acute effect of urea infusion on phenobarbital concentrations in rats at onset of loss of righting reflex. J. Pharmacol. Exp. Ther. 232: 430-435 (1985)
- 459 M. Danhof and G. Levy: Kinetics of drug action in disease states. IV. Effect of pregnancy on phenobarbital concentrations at onset of loss of righting reflex in rats. J. Pharmacol. Exp. Ther. 232:426-430 (1985)
- 460 C.H. Kleinbloesem, P. van Brummelen, H. Faber, M. Danhof, N.P. Vermeulen and D.D. Breimer: Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism. Biochem. Pharmacol. 33: 3721-3724 (1984)
- 461 M. Danhof, M. Hisaoka and G. Levy: Kinetics of drug action in disease states. II. Effect of experimental renal dysfunction on phenobarbital concentrations in rats at onset of loss or righting reflex. J. Pharmacol. Exp. Ther. 230:627-631 (1984)
- 462 M. Danhof and G. Levy: Kinetics of drug action in disease states. I. Effects of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex. J. Pharmacol. Exp. Ther. 229:44-50 (1984)
- 463 M. Danhof and M.W.E. Teunissen: Antipyrine as a model drug to assess oxidative drug metabolizing activity in man. Pharmacy International 5: 11-15 (1984)
- 464 N.P.E. Vermeulen, M. Danhof, I. Setiawan and D.D. Breimer: Disposition of hexobarbital in the rat: estimation of "first pass" effect and influence of ether anesthesia.

- J. Pharmacol. Exp. Ther. 226:201-205 (1983)
- 465 M. Danhof, R.M.A. Verbeek, C.J. van Boxtel, J.K. Boeijinga and D.D. Breimer: Differential effects of enzyme induction on antipyrine metabolite formation. Br. J. Clin. Pharmacol. 13:379-386 (1982)
- 466 M. Danhof, A. Van Zuilen, J.K. Boeijinga and D.D. Breimer: Studies on the different metabolic pathways of antipyrine in man. Oral vs. IV administration and the influence of urinary collection time. Eur. J. Clin. Pharmacol. 21:433-441 (1982)
- 467 M. Danhof, M.W.E. Teunissen and D.D. Breimer: 3-Hydroxy-methylantipyrine excretion in urine after an oral dose of antipyrine: A reconsideration of previously published data and synthesis of a pure reference substance. Pharmacology 24:181-184 (1982)
- 468 M. Danhof, J.R. Idle, M.W.E. Teunissen, T.P. Sloan, D.D. Breimer and R.L. Smith: Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation. Pharmacology 22:349-358 (1981)
- 469 N. Buchanan, M. Davis, M. Danhof and D.D. Breimer: Antipyrine metabolite formation in children in the acute phase of malnutrition and after recovery. Br. J. Clin. Pharmacol. 10:363-368 (1980)
- 470 D.D. Breimer and M. Danhof: Saliva, a fluid for measuring drug concentrations. Pharmacy International 1:9-11 (1980)
- 471 M. Danhof, D.P. Krom and D.D. Breimer: Studies on the different metabolic pathways of antipyrine in rats. Influence of phenobarbital and 3-methylcholanthrene treatment. Xenobiotica 9:695-702 (1979)
- 472 M. Danhof and D.D. Breimer: Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers. Br. J. Clin. Pharmacol. 8:529-537 (1979)
- 473 M. Danhof: The assessment of drug metabolizing capacity in man. Pharm. Weekblad 114:129-149 (1979)
- 474 M. Danhof, A.G. de Boer, E. De Groot-Van der Vis and D.D. Breimer: Assay of 3-carboxy-antipyrine in urine by capillary gaschromatography with nitrogen selective detection: some preliminary results in man. Pharmacology 19:215-220 (1979)
- 475 M. Danhof, E. De Groot-Van der Vis and D.D. Breimer: Assay of antipyrine and its primary metabolites in plasma, saliva and urine by HPLC and some preliminary results in man. Pharmacology 18:210-223 (1979)
- 476 R.J. Vonk, M. Danhof, A.P.A.T. Coenraads, A.B.D. Van Doorn, K. Keulemans, A.H.J. Scaf and D.K.F. Meijer: Influence of bile salts on hepatic transport of dibromosulphophtalein. Am. J. Physiol. 237: E524-E534 (1979)
- 477 M. Danhof, B.M.J. Loomans and D.D. Breimer: Assay of theophylline in plasma and saliva in the presence of caffeine metabolites. Pharm. Weekblad 113:672-676 (1978)
- 478 M. Danhof and D.D. Breimer: Therapeutic drug monitoring in saliva. Clin. Pharmacokin. 3:39-57 (1978)

Publications in books:

1. S. Schmidt, T.M. Post, M. Boroujerdi, C. van Kesteren, B.A. Ploeger, O.E. Della Pasqua, M. Danhof (2010) Disease progression analysis: towards mechanism-based models. In: Clinical Trial Simulations – Applications and Trends Ed. H. Kimko and CC Peck, Springer, New York.
2. M. Danhof, P.H. van der Graaf, D.M. Jonker, S.A.G. Visser en K.P. Zuideveld (2007) Mechanism-based pharmacokinetic/pharmacodynamic modeling for the prediction of in vivo drug concentration-effect relationships-application in drug candidate selection and lead optimization. In: Comprehensive Medicinal Chemistry II, Part 5 Ed. B. Testa and H. van de Waterbeemd, Elsevier Science Publishers, Oxford, pp 885-908.
3. M. Danhof, PH van der Graaf, SAG Visser, KP Zuideveld (2004). Mechanism-based pharmacodynamic modelling for prediction of exposure response. In: Advanced Methods of Pharmacokinetic & Pharmacodynamic Systems Analysis Volume 3, Ed. D.Z. D'Argenio, Kluwer Academic Publishers, Boston, pp 49-65.
4. M. Danhof. Mechanism-based modelling of CNS drug effect: from receptor pharmacology to clinical trial. In: Optimal Dose Identification, Ed A. Breckenridge, Excerpta Medica, pp 79-85, 2001
5. T. van Laar, R. van der Geest and M. Danhof. Future delivery systems for apomorphine in patients with Parkinson's disease. Parkinson's disease: Advances in Neurology, Ed. by Gerald M. Stern, Lippincott Williams & Wilkins, Philadelphia. 1999, Vol.80: 535-544.
6. E.C.M. De Lange, M. Danhof, A.G. De Boer and D.D. Breimer: Effects of perfusate tonicity and temperature on microdialyze AUC values of acetaminophen and atenolol obtained from rat cortical brain. In: Drug transport across the blood-brain barrier. A.G. De Boer and W. Sutanto (eds.), Harwood Academic Publishers, Amsterdam, part B, 1997, pp.157-163.
7. P.H. van der Graaf, E.A. Van Schaick and M. Danhof: Mechanism-based modelling of drug-receptor interactions in vivo: a population approach. In: The population approach: measuring and managing variability in response, concentration and dose. L. Aarons, L.P. Balant, M. Danhof, M. Gex-Fabry, U.A. Gundert Remy, M.O. Karlsson, F. Mentré, P.L. Moreselli, F. Rombout, M. Rowland, J.-L. Steimer and S. Voseh (eds.). Office for official publications of the European Communities, Luxembourg, 1997, pp. 329-335.
8. M. Danhof, J.W. Mandema and C. Hoyo-Vadillo: Modelling of pharmacodynamic drug-drug interactions. In: Drug Interaction Studies During Drug Development (J. Kuhlmann, ed.) W. Zuckschwerdt Verlag, München, 1994, pp. 55-60.
9. M. Danhof and J.W. Mandema: Modelling of relationships between pharmacokinetics and pharmacodynamics. In: Pharmacokinetics (P.G. Welling, F. Tse, eds.), Marcel Dekker, New York, 1994, pp. 139-174.
10. M. Danhof and R.A. Voskuyl: Pharmacokinetic/pharmacodynamic correlations of anticonvulsants. In: Handbook on Pharmacokinetic-Pharmacodynamic Correlations (H. Derendorf, ed.) CRC Press Inc., Boca Raton, 1994, pp. 185-196.
11. E.C.M. de Lange, M. Danhof, A.G. de Boer and D.D. Breimer: The use of intracerebral microdialysis to study blood-brain barrier transport in health, after modification and in disease. In: Frontiers in Cerebral Vascular Biology (L.R. Drewes and A.L. Betz, eds.), Plenum Press, New York, 1993, pp. 257-262.

12. M. Danhof, R.A. Voskuyl and A. Hoogerkamp: Preclinical and clinical pharmacodynamics of anticonvulsants. In: The In Vivo Study of Drug Action - Concepts and Applications of Kinetic-Dynamic Modelling (C.J. van Boxtel, N.H.G. Holford and M. Danhof eds.), Elsevier Science Publishers, Amsterdam, 1992, 179-203.
13. M. Danhof, J.W. Mandema and A.M. Stijnen: Pharmacokinetic complexities of in vivo pharmacodynamic investigations. In: The In Vivo Study of Drug Action - Concepts and Applications of Kinetic-Dynamic Modelling (C.J. van Boxtel, N.H.G. Holford and M. Danhof, eds.), Elsevier Science Publishers, Amsterdam, 1992, pp. 31-60
14. M. Danhof, J.W. Mandema and A. Hoogerkamp: Preclinical pharmacodynamics of central nervous system active agents. In: Integration of Pharmacokinetics, Pharmacodynamics and Toxicokinetics in Rational Drug Development (A. Yacobi, J. Skelly, V. Shah and L.Z. Benet eds.) 1992, 69-80.
15. M. Danhof: Parenteral neuropharmacological kinetics: pharmacokinetic aspects of controlled drug delivery to the brain. In: Parenteral Drug Therapy in Spasticity and Parkinson's Disease (J.P.W.F. Lakke, ed), Parthenon Press, Carnforth, 1991, pp. 163-176.
16. J.B.M.M. van Bree, A.G. de Boer, M. Danhof and D.D. Breimer. Transport of drugs across the blood-brain barrier: In vitro and in vivo strategies. In: Pharmaceutical applications of cell and tissue culture (G. Wilson, S.S. Davis and L. Illum, eds.) NATO ASI Series, Plenum, New York, 1991, pp. 175-189.
17. M. Danhof: Pharmacology of Hypnotics in the Elderly. In: Sleep and Ageing (S. Smirne, ed.), Masson, SA, Milano, 1991, pp. 217-224.
18. M. Danhof: Does variability in drug disposition explain (all) variability in drug effects? In: Topics in Pharmaceutical Sciences 1989 (D.D. Breimer, K.K. Midha and D.J.A. Crommelin eds.). Federation Internationale Pharmaceutique, The Hague, 1989, pp. 573-789
19. A.M. Stijnen, S.H. van der Voort, C.F.A. van Bezoooyen and M. Danhof: The influence of ageing on the pharmacokinetics and pharmacodynamics of barbiturates. In: The Liver, Metabolism and Ageing. (K.W. Woodhouse, C. Yelland and O. James, eds.) EURAGE, Rijswijk, 1989 pp. 57-65
20. M. Danhof: Drugs and ageing: pharmacokinetics vs pharmacodynamics. In: The Liver, Metabolism and Ageing. (K.W. Woodhouse, C. Yelland and O. James, eds.) EURAGE, Rijswijk 1989 pp. 43-57
21. R.A. Voskuyl, H. Meinardi, J. Dingemanse, M. Danhof and D.D. Breimer: Correlation of serum levels and anticonvulsive effect of diazepam and oxazepam in rats determined by cortical stimulation. In: Advances in Epileptology Vol. 17. Raven Press, New York, 1989 pp 215-218
22. M. Danhof: Single versus chronic dosing in the safety evaluation of xenobiotics: Pharmacokinetic considerations. In: Drug Metabolism from Molecules to Man (D.J. Benford, J. W. Bridges and G.G. Gibson, Eds.). Taylor and Francis, London, 1987, pp 531-547
23. M. Danhof, J. Dingemanse and D.D. Breimer: Determination of benzodiazepines in biological fluids- the present day scene. In: Bioactive Analytes Including Antipsychotics and Peptides (E. Reid & B. Scales, eds.), Plenum Press, New York, 1986, pp 141-148

24. M. Danhof: Factors affecting the relationship between pharmacokinetics and anesthetic effects of barbiturates. In: Intravenöse Narkosemittel. (C. Lehmann, B. Landauer and N. Roth, eds) Perimed Fachbuch Verlags gesellschaft, Erlangen, 1984, pp 23-29
25. D.D. Breimer, N.P.E. Vermeulen, M. Danhof, M.W.E. Teunissen, R.P. Joeres and M. Van der Graaff: Assessment and prediction of oxidative drug metabolizing activity in vivo. In: Pharmacokinetics, a modern view (L.Z. Benet, G. Levy and B.L. Ferraiolo, eds) Plenum Press, New York, 1984, pp 191-217
26. M. Danhof and D.D. Breimer: Urinary metabolite profile of antipyrine as a tool in the assessment of oxidative drug metabolizing capacity in man. In: Methods in Clinical Pharmacology (N. Rietbrock, G. Neuhaus and B.G. Woodcock, eds), Friedrich Vieweg und Sohn Verlags gesellschaft, Braunschweig, 1980, pp 176-186
27. D.D. Breimer and M. Danhof: Interindividual differences in pharmacokinetics and drug metabolism. In: Towards a better safety of drugs and pharmaceutical products (D.D. Breimer, ed) Elsevier/North-Holland Bio-medical Press, Amsterdam, 1980, pp 117-142

Invited Lectures at International Conferences:

1. Future Medicines for one world – the promise of patient empowerment; 79th FIP Congress on Pharmacy and Pharmaceutical Science, Abu Dhabi, 23 September 2019.
2. Future medicines for one world – systems approaches to drug discovery, development and clinical usage. DPhG Jahrestagung, Saarbrücken, 29 September, 2017
3. Systems approaches – a European view on pharmaceutical sciences 2020, 2nd Congress of Pharmacists from Montenegro, Becici, 29 May 2015
4. Systems approaches: a European view on pharmaceutical sciences 2020, 3rd Congress of pharmacists of Bosnia Herzegovina, Sarajevo, May 14, 2015
5. Systems pharmacology – towards the modeling of network interactions, Global Gator Meeting Utrecht, 6 May 2015
6. Systems approaches – towards precision treatments. Dubai Pharmaceutical and Technology Conference, Dubai, 10 March 2015
7. Systems Pharmacology – towards multi-target therapy 3rd HD Physiology Symposium, Osaka, 6 March 2015
8. Systems approaches: a European view on pharmaceutical sciences 2020; Romanian National Congress on Pharmaceutical Sciences, Iasi, 25 September 2014
9. Pharmacokinetic and pharmacodynamic concepts in dosage regimen design 74th FIP Congress on Pharmacy and Pharmaceutical Science, Bangkok, 1 September 2014
10. Systems pharmacology-towards precision treatments. 10th Central European Symposium on Pharmaceutical Technology, Portoroz, September 14, 2014
11. Systems Pharmacology towards multi-target therapeutic interventions 5th FIP Pharmaceutical Sciences World Congress, Melbourne, April 14, 2014
12. A European View on Pharmaceutical Sciences 2020, 5th FIP Pharmaceutical Sciences World Congress, Melbourne, April 13, 2014
13. Mechanism-based PKPD modeling – towards prediction of drug effect. International Symposium on Past, Present and Futures of Molecular Pharmacokinetics. Tokyo, January 16, 2012

14. Mechanism-based PKPD modeling- principle and applications, 10th Congress of EACPT, Budapest, June 27, 2011
15. Mechanism-based PKPD modeling-towards systems pharmacology. EUFEPS Pharmaceutical Sciences Fair, Prague, June 16, 2011.
16. Mechanism-based pharmacokinetics and pharmacodynamics in translational drug research. Annual Meeting of the Academy of Pharmaceutical Sciences and Technology of Japan, Tokyo, May 30, 2011.
17. Mechanism-based PKPD modeling in translational pharmacology. PhysPhar Meeting, Liege, March 18, 2011.
18. PKPD in translational pharmacology-towards mechanism-based models. AAPS Annual Meeting/FIP Pharmaceutical Sciences World Congress, New Orleans, November 17, 2010.
19. Mechanism-based PKPD for Translation. AAPS Annual Meeting/FIP Pharmaceutical Sciences World Congress, New Orleans, November 16, 2010.
20. Disease systems analysis: utility of collaborative data resources. AAPS Annual Meeting/FIP Pharmaceutical Sciences World Congress, New Orleans, November 15, 2010
21. Quantitative systems pharmacology: what are the targets? 6th International Symposium on Measurement and Kinetics of *In Vivo* Drug Effects, Noordijkerhout, the Netherlands, April 22, 2010.
22. PKPD modeling in pharmacology: towards mechanism-based models. TIPharma BioLogue Workshop “Modeling and simulation approaches in drug discovery and development”, Copenhagen, Denmark, November 19, 2009 and Leiden, the Netherlands, November 24, 2009.
23. TIPharma Mechanism-based PKPD modeling platform. American Conference on Pharmacometrics, Mashantucket, October 5, 2009.
24. PKPD in clinical pharmacology: towards mechanism-based models. ACCP, 37th. Annual Meeting, San Antonio, September 13, 2009.
25. Systems pharmacology in translational medicines research. Gerhard Levy Distinguished Lectureship in Pharmaceutical Sciences, Buffalo, October 16, 2008.
26. Mechanism-based PK-PD modeling for prediction of efficacy-safety. GPEN, Leuven, September 11, 2008.
27. Translational medicine: bridging the gap using mechanism-based PK-PD modeling, ICPM, Amsterdam, September 7, 2008.
28. Tutorial on Implementing Receptor Theory in PK-PD modeling, PAGE, Marseille, June 19, 2008
29. PK-PD in pediatric clinical pharmacology: towards mechanism-based models? ESDP, Rotterdam, June 5, 2008
30. Mechanism-based PK-PD modeling for prediction of efficacy and safety. Bioscience Initiative Lecture, Leiden, May 29, 2008
31. Translational PK/PD: bridging the preclinical-clinical gap using mechanism-based modeling and simulation. ASCPT, Orlando, April 5, 2008.
32. Mechanism-based PK-PD modeling for prediction of efficacy-safety in drug development. 128th Annual Meeting of the Pharmaceutical Society of Japan.” Tokyo, March, 2008.
33. Mechanism-based PK-PD modeling for prediction of efficacy-safety. GRUM, Montreal, March 7, 2008.
34. Mechanism-based PK-PD modeling for predicting exposure response. ACOP, Tucson, Arizona, March 9-12, 2008

35. Mechanism-based PK-PD modeling: utility for prediction of efficacy-safety. Safety Pharmacology Society, Edinburgh, September 21, 2007
36. State-of-the-art PK-PD modeling theory & concepts. EUFEPS, Basel, December 6, 2007
37. Pharmacodynamic and disease system analysis. Lewis B. Sheiner Memorial Symposium, Washington, December 4-5, 2006.
38. Mechanism-based PK-PD modeling for prediction of efficacy-safety. ISSX, Sendai, October 12, 2007
39. Mechanism-based PK-PD modeling of CNS drugs. Towards predictive safety. Safety Pharmacology Society, Sandwich, UK, February 13, 2007.
40. Mechanism-based PK-PD to predict pharmacodynamics in human. 4th James Black Conference, Hertfordshire, UK, September 11-13, 2006.
41. Mechanism-based PK-PD modeling for prediction of efficacy and safety. British Pharmaceutical Conference, Manchester, 10 September 2007.
42. Pharmacokinetic-Pharmacodynamic Correlations in Psychopharmacology. European Behavioral Pharmacology Society, Tübingen, September 3, 2007.
43. Mechanism-based modeling of the efficacy-safety of (semi-) synthetic opioids. A tribute to Jim G. Bovill. Jim G Bovill, Afscheidsymposium, Leiden, January 19, 2007.
44. Academic perspective on the current status and future directions of PK/PD modeling. 5th International Symposium on Measurement and Kinetics of In Vivo Drug Effects, Noordwijkerhout, the Netherlands, April 26-29, 2006.
45. What can and should we measure? Biomarkers and Surrogate Endpoints. MRC Workshop "Disease, Drugs and Patient Benefit-Can Biomarkers Deliver", London, January 31, 2006.
46. Mechanism-based PK/PD modeling for prediction of pharmacodynamics in human. British Pharmacological Society Winter Meeting, December 19, 2005.
47. Pathophysiological Pharmacometrics: Lessons from Predictive Pharmacology. ECPM/EUFEPS Workshop "The Risk-Benefit Balance in Drug Development", Basel, September 29, 2005
48. Mechanism-based Disease Progression Analysis Application to type 2 Diabetes Mellitus. Annual Meeting of MUFPADA, Indianapolis, April 29, 2005
49. Mechanism-based PK/PD Modelling Role of Biomarkers The 15th Keio University International Symposium for Life Sciences and Medicine, Tokyo, Japan, January 25-26, 2005.
50. Systems Biology to Predict Pharmacodynamics in Human 8th Congress of the European Federation of Pharmaceutical Sciences, Brussels, October 18-20, 2004.
51. Biomarkers & Mechanism-Based Pharmacodynamic Modelling: a Perfect Symbiosis Rösenö Meeting on "Use of biomarkers in PK/PD driven Drug Discovery and Development", Stockholm, August 26-28, 2004
52. Mechanism-based PK/PD Modelling for Prediction of Exposure Response. 2nd Pharmaceutical Sciences World Conference, Tokyo, May 29 - June 3, 2004
53. Mechanism-based PK/PD: from Receptor Pharmacology to Clinical Trial and Beyond 2004 ASCPT Annual Meeting, Miami, March 23-27, 2004
54. Mechanism-based PK/PD Modelling: from Receptor Pharmacology to Clinical Trial. Drug Research Academy. Middelfart, Denmark, August 28-29, 2003
55. Development, Evaluation and Validation of Biomarkers: Mechanism-based PK/PD Modelling. 6th EACPT Congress, Istanbul, Turkey June 25-26, 2003

56. Mechanism-based Pharmacodynamic Modelling for Prediction of Exposure Response. 10th BMSR Workshop on Advanced Methods of Pharmacokinetic and Pharmacodynamic Analysis. Marina del Rey, USA, June 20-21, 2003
57. Mechanism-based PK/PD modeling: From receptor pharmacology to clinical trial. 17th JSSX Workshop, Tokyo, Japan, April 16-18, 2003
58. EEG parameters as Biomarkers Extrapolation from Laboratory Animals to Humans. IPEG Meeting, Barcelona, Spain, November 23-24, 2002
59. Pharmacology-EEG and PK/PD Modelling in Drug Development. IPEG Meeting, Barcelona, Spain, November 23-24, 2002
60. Incorporation of Receptor Theory in PK/PD modelling: A1 Adenosine, OP3 Opioid, 5-HT1A Serotonin and GABAA Receptors. 4th International Symposium on Measurement and Kinetics of In vivo Drug Effects, Noordwijkerhout, April 24-27, 2002
61. Biomarkers Mechanism-Based PK/PD Modelling. DIA Workshop, "Statistical Methodology in Clinical R&D". Venice, Italy, April 8-10, 2002
62. Mechanism-Based PK/PD Modelling Application in Drug Candidate Selection and Lead Optimisation. World Congress of Pharmacy and Pharmaceutical Sciences – 61st FIP Congress, Singapore, September 1-6, 2001.
63. Mechanism-based PK/PD Modelling: Incorporation of Receptor Theory and Dynamic Systems Analysis. 9th BMSR Workshop on Advanced Methods of Pharmacokinetic and Pharmacodynamic Analysis. Marina del Rey, USA, June 22-23, 2001
64. Mechanism-based PK/PD Modelling: Incorporation of Receptor Pharmacology, Scheele Symposium. "PK/PD an Increasing Role in Preclinical and Clinical Drug Development". Swedish Pharmaceutical Society Stockholm, October 11, 2000
65. Mechanism-based modelling of CNS Drug Effect: from Receptor Pharmacology to Clinical Trial. Esteve Symposium "Optimal Dose Identification", Barcelona, Spain, October 4-7, 2000
66. Pharmacodynamics: Role in Improving Drug Therapy. "Quantitative Methodologies to Improve Drug Development & Therapy", Symposium in honour of L.B. Sheiner, San Francisco, U.S.A., May 26-27, 2000
67. Pharmacokinetic-Pharmacodynamic Relationships: Future Strategies. "Mechanism-Based Pharmacokinetics and Pharmacodynamics, Symposium" in Honour of D.D. Breimer, LACDR, Leiden, The Netherlands, May 19, 2000
68. PK/PD Technology for Optimisation of Early Stage Drug Development, Meeting of the UK "Drug Metabolism Group" Manchester, UK, February 10, 2000
69. In vitro/In Vivo Modelling of Receptor Mediated Pharmacological Responses. 6th Congress of the European Federation of Pharmaceutical Sciences, Budapest, September 17-19, 2000
70. New Developments in PK/PD Modelling VI th IUPHAR World Conference on Clinical Pharmacology and Therapeutics, Florence, July 15-20, 2000.
71. Whole Body Receptor Oriented PK/PD for early Acceleration of Medicinal Product Development 11th International Conference on Pharmaceutical Medicine, Berlin, June 4-7, 2000
72. Whole Animal Receptor Oriented PK/PD for Early Acceleration of Drug Development. Millenial World Congress of Pharmaceutical Sciences, San Fransico, April 16-20, 2000.
73. Influence of Age on the Pharmacokinetic/Pharmacodynamic Relationships of CNS Active Drugs Asian Conference and Exhibition of Controlled Release, Hongkong, November 29-30, 1999.

74. Prediction of Human Pharmacology from Animal Studies: Utility of Pharmacodynamic Markers. AAPS Annual Meeting, New Orleans, November 14-18, 1999.
75. Integrated Pharmacokinetic-Pharmacodynamic Modelling as a Basis for Rational Drug Design American Chemical Society 218th National Meeting, New Orleans, August 22-26, 1999.
76. Whole Animal Receptor Oriented PK/PD Modelling: Application in Drug Discovery and Development. 5th Congress of the European Federation of Pharmaceutical Sciences (EUFEPS), Jerusalem, April 25-29, 1999.
77. Mechanism-based PK/PD Modelling ECPM Workshop "Frontiers in Drug Development-Streamlining Proof of Principle". Basel, March 4, 1999
78. Whole Animal Receptor Oriented PK/PD for Early Acceleration of Drug Development 5th Nuremberg EUFEPS Conference "Optimising Drug Development: Fast Tracking into Human", Wiesbaden, December 7-9, 1998.
79. Measurement and Kinetics of In Vivo Drug Effects. Summary, Conclusions and Perspectives. 3rd International Symposium on Measurement and Kinetics of In vivo Drug Effects, Noordwijkerhout, May 27-30, 1998.
80. Whole Animal Receptor Oriented PK/PD for Early Acceleration of Drug Development. Symposium "Clinical Development of New Drugs and Therapeutic Agents: Art, Science and New Frontiers", McClean, Virginia, May 12-15, 1998.
81. Whole Animal Receptor Oriented PK/PD as a Predictive Tool for Clinical Trials. Rosenö Meeting on Trends in Pharmacokinetics and Dynamics. From Drug Development to Patient Care, Stockholm, April 23-25, 1998.
82. Mechanism-based Pharmacokinetic/Pharmacodynamic Modelling: Application in the Design of Selective Adenosine A1 Receptor Agonists. 1997 Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, November 2-6, 1997.
83. Mechanism-Based Pharmacokinetic Pharmacodynamic Modelling: Application in the Design of Selective Adenosine A1 Receptor Agonists. The 7th BMSR Workshop, University of Southern California, Los Angeles May 16-17, 1997.
84. Whole Animal Receptor Oriented PK/PD for Early Acceleration of Drug Development. Symposium "Clinical Development of New Drugs and Therapeutic Agents: Art, Science and New Frontiers", Stanford University, California, July 8-11, 1997.
85. Mechanism-based Modelling of Drug-Receptor Interactions In Vivo: A Population Approach, COST B1, Conference "The population approach: measuring and managing variability in response, concentration and dose", Geneva, February 12-14, 1997.
86. Analysis of Drug-Receptor Interactions In Vivo: A New Approach in Pharmacokinetic-Pharmacodynamic Modelling, AGAH Annual Meeting " The physiological basis of PK/PD Modelling", Neu-Ulm, February 3-4, 1997.
87. Application of PK/PD Research in Rational Drug Development, XIII Congreso de la Sociedad Española de Farmacología Clínica, Barcelona, November 27-29, 1996
88. Pharmacokinetic/Pharmacodynamic Modelling: Extrapolation from Animals to Humans, 3rd European Congress of Pharmaceutical Sciences, Edinburgh, September 15-17, 1996
89. Transdermal Iontophoretic Delivery of R-Apomorphine in Parkinson's Disease, 3rd Jerusalem Conference on Pharmaceutical Sciences and Clinical Pharmacology, Jerusalem, September 1-6, 1996
90. Pharmacokinetic/Pharmacodynamic Correlations of Anaesthetic Drugs. Symposium 'Target Controlled Infusion', Cambridge, September 12-14, 1995.

91. The Importance of Using Controlled Release Products for CNS Active Drugs. FIP-Satellite Symposium on 'Optimizing Therapy Using Controlled Release Products', Stockholm, August 25-26, 1995.
92. Pharmacokinetic/Pharmacodynamic Relationships. Symposium 'Current Concepts, New Approaches and Practical Applications in Pharmacokinetics', London, October 6-7, 1994.
93. Overview of Pharmacodynamic Modelling: Experimental Design Issues. Annual Meeting of the Association of University Anesthesiologists, Chicago, May 3-5, 1994
94. Pharmacokinetic and Pharmacodynamic Modelling of the Effects of Psychotropic Drugs in Animals and in Man. Meeting of the French Pharmacological Society, Paris, April 22, 1994
95. Pharmacokinetic/Pharmacodynamic Modelling of the Effects of Adenosine Receptor Agonists and Antagonists: Application in Drug Design. Second International Symposium on Measurement and Kinetics of In Vivo Drug Effects, Noordwijkerhout, April 14-16, 1994.
96. Pharmacokinetic-Pharmacodynamic Modelling with Enantiomeric Drugs: Phenylisopropyl-adenosine, Baclofen and Hexobarbital. Rosenon Conference of the Swedish Pharmaceutical Society, Stockholm, March 14-17, 1994.
97. Controlled Delivery of Calcium Antagonists - Pharmacokinetic and Pharmacodynamic Aspects. European Meeting on Calcium Antagonists, September 14-17, 1993.
98. Modelling of Pharmacodynamic Drug-Drug Interactions. Symposium "Arzneimittel Interaktionen: Mechanismen und Klinische Relevanz", Bad Nauheim, September 4, 1993
99. Pharmacodynamics and Pharmacodynamic Interactions of CNS active Drugs. BMSR Workshop on "Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis", Los Angeles, May 21-23, 1993.
100. Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives. Vth European Congress of Biopharmaceutics and Pharmacokinetics, Brussels April 20-22, 1993.
101. Pharmacokinetic-Pharmacodynamic Correlations of Drugs Acting at Benzodiazepine Receptor Sites. Symposium "Pharmacokinetic-Pharmacodynamic Correlations in Clinical Neuropsychopharmacology", Milan, March 26, 1993.
102. Application of Microdialysis to Determine Blood-Brain Barrier Transport of Drugs. Symposium "Drug Transport to the Brain: Concepts and Strategies". Leiden, October 9-11, 1992.
103. Integrated Pharmacokinetic/Pharmacodynamic Approaches in Preclinical and Clinical Investigations with CNS active Drugs. First European Congress on Pharmaceutical Sciences, Amsterdam, October 7-9, 1992.
104. Modelling of the pharmacodynamics and pharmacodynamic interactions of CNS-active drugs. Second Annual Conference of the Society of Clinical Pharmacology, Rostock, September 9-12, 1992.
105. Pharmacodynamics of the anticonvulsant effect of benzodiazepines: relationship with interactions at the GABA-Benzodiazepine receptor complex. 6th Japanese-American Conference on Pharmacokinetics and Biopharmaceutics, Buffalo, August 1-3, 1992
106. Variability in pharmacodynamics of CNS active drugs: effects of ageing versus disease. Second Jerusalem Conference on Pharmaceutical Sciences and Clinical Pharmacology. Jerusalem, May 24-29, 1992.

107. Pharmacodynamic Drug-Drug Interactions: Theoretical Considerations and Methods of Investigation. First International Boerhaave Conference on Drug-Drug and Drug-Food Interactions, Leiden, May 2-3, 1991.
108. Preclinical Pharmacodynamics of Central Nervous System Active Agents. Conference on Integration of Pharmacodynamics, Pharmacokinetics and Toxicokinetics in Rational Drug Development, Washington, April 24-26, 1991.
109. Role of Pharmacokinetics and Pharmacodynamics in CNS Drug Development. Annual Meeting of the American College of Neuropharmacology, Puerto Rico, 10-14 December 1990
110. Workshop on Application of Pharmacokinetic-Pharmacodynamic Modelling Concepts in Drug Development, Paris, 7 December 1990
111. Pharmacokinetic-pharmacodynamic modelling studies with CNS drugs in an animal model of ageing. 5th Annual Meeting of "Pharmacokinetics UK" Cheltenham, 7-9 November 1990
112. Parenteral neuropharmacological kinetics. 8th European Workshop of the European Association for Clinical Neuropharmacology, Groningen 27-29 September 1990
113. Measures of Anticonvulsant Intensity: a Pharmacological Evaluation. IUPHAR Satellite Symposium: Measurement and kinetics of in vivo drug effects, Noordwijk, 28-30 June 1990.
114. Pharmacology of hypnotics in the elderly. Second Milano International Symposium on Sleep, Milano, 12-14 October, 1989
115. Does variability in drug disposition explain all variability in drug effects? 49th Congress of Pharmaceutical Sciences of FIP, Munich, 4-8 September 1989
116. Measurement and Kinetics of drug effects on the central nervous system. BMSR Workshop on Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis, Los Angeles, 19-20 May, 1989
117. Simultaneous pharmacokinetic-pharmacodynamic modelling. 90th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Nashville, 8-10 March, 1989
118. Drugs and ageing: Pharmacokinetics vs pharmacodynamics. EURAGE Meeting, Nerja, Spain, 17-19 November 1988
119. Effect of rate and route of administration on drug response. Symposium on Variability in Pharmacokinetics and Drug Response, Gothenburg, 3-5 October 1988
120. Single versus chronic dosing in the safety evaluation of xenobiotics: Pharmacokinetic considerations. Xth European Workshop on Drug Metabolism, Guildford, 6-11 July 1986
121. Verapamil Sustained Release Tablets: Kinetic and Dynamic Properties in healthy Volunteers. Congress: Hypertension - The Next Decade, Berlin, 10-11 October 1985.
122. Determination of Benzodiazepines-The Present Day Scene. Sixth Bio-Analytical Forum, Guildford, 10-13 September 1985
123. Factors Affecting the Relationship between Pharmacokinetics and Anesthetic Effects of Barbiturates. Symposium: Intravenöse Narkosemittel, München, 2-3 December 1983
124. Factors and Conditions Affecting Antipyrine Metabolite Formation in Man. IUPHAR Satellite Symposium: The Value of Antipyrine and Aminopyrine as Model Substrates in Assessing Drug Metabolizing Capacity in Man. Leiden, 1-3 August 1980

125. Methodology of Measuring Antipyrine Metabolites: Influence of Route of administration, dose, intra- en inter-subject variation. IUPHAR Satellite Symposium: The Value of Antipyrine and Aminopyrine as Model Substrates in Assessing Drug Metabolizing Capacity in Man, Leiden, 1-3 August 1980
126. Studies on the Different Metabolic Pathways of Antipyrine. Symposium of the Drug Metabolism Group of the British Pharmacological Society, Manchester, 21 February 1979
127. Analysis of Drugs in Saliva. Symposium: Drug Analysis in Biological Material - Principle Aspects, Stockholm. 1-3 November 1978